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This thesis describes the development and subsequent use of
a high-performance liquid chromatographic technique for the
measurement of the melanin precursor 5-S-cysteinyldopa (5-S-CD)
in plasma, using its diastereomer, 5-S-D-cysteinyl-L-dopa as
internal standard. The assay developed had a between-batch
coefficient of variation (CV) of less than 4 percent, and was
sufficiently sensitive to detect picogram quantities of 5-S-CD.
The method was used to assess the value of plasma 5-S-CD as
a marker for the melanocytic tumour, malignant melanoma.
Study of healthy volunteers established an upper limit of
normal for plasma 5-S-CD of 20nmol per litre, and also demonstrated
the changes in plasma 5-S-CD which occurred in individuals through¬
out the year in Edinburgh. Skin pigmentation and hair colour did
not influence plasma 5-S-CD levels, but exposure to ultraviolet
radiation (UVR) in the form of photochemotherapy (PUVA) or short
wave UVR therapy (UVB) was shown to increase plasma 5-S-CD levels
dramatically in psoriatic patients.
Patients with a variety of tumours were studied. Plasma
5-S-CD levels were not raised in patients with primary melanoma
or in patients with non-melanoma tumours, such as breast, lung,
and stomach cancer. Elevated levels were found in 60 percent of
patients with secondary melanoma, in some cases before the second¬
ary tumour was detectable by clinical means.
Impaired liver function did not, in general, affect plasma
5-S-CD levels, but raised levels were seen in a high proportion
of patients with impaired renal function. Raised levels were
also found in patients with Parkinson's disease who were under¬
going treatment with dopa and carbidopa.
The finding that patients with tyrosinase-negative oculo¬
cutaneous albinism had normal levels of plasma 5-S-CD led to
(vi)
some consideration of possible non-tyrosinase mechanisms for the
generation of this amino acid.
In conclusion, the measurement of plasma 5-S-CD was shown to
be of use in the early detection of metastatic disease in a propor¬
tion of patients with malignant melanoma, but the value of this
test was found to be limited by a number of factors, the most sig¬
nificant being the number of patients in whom the presence of
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The main purpose of the work presented in this thesis was
to study the amino acid 5-S-cysteinyldopa (5-S-CD) in plasma,
and to examine its use as a tumour marker for malignant melanoma.
5-S-CD is an intermediate in the synthesis of melanin, and this
introduction will, therefore, review melanin synthesis, before
turning to malignant melanoma and summarising progress in the
search for a specific and sensitive marker for this tumour.
Melanin Pigmentation and Skin Colour
Normal human skin colour depends upon the presence of four
pigments; haemoglobin, oxyhaemoglobin, melanin and carotenoids.
The pink appearance of the untanned Caucasoid is due to the
pigment oxyhaemoglobin in the blood within the capillary plexus
of the superficial dermis. Carotene, a yellow pigment, is found
in the subcutaneous fat and epidermis. Skin pigmentation is
the result of the balance between these factors and melanin, the
major determinant of skin colour. Variation in the melanin
pigmentation of the skin accounts for the wide spectrum of human
skin colour (Hunter, 1977).
meaning black. In fact this group of pigments includes the black
or brown nitrogenous eumelanins, the yellow or reddish brown
sulphur-containing phaeomelanins, and other pigments whose physical
and chemical properties are intermediate between those of the
eumelanins and the phaeomelanins (Prota, 1980).
Melanins are found in virtually all groups of living organisms
including higher plants, fungi and bacteria. In the human,
melanin is produced solely by cells known as melanocytes. These
cells are present in the skin, the uveal tract of the eye, and
the leptomeninges, having migrated to these positions from the
neural crest early in foetal life (Rawles, 1948). In normal skin
melanocytes are dendritic cells situated just above the basal
lamina, and their dendrites project between the surrounding keratin
ocytes, situated in the lower epidermis (Fig. 1.1). Each












FIGURE 1.1 Diagramatic representation of the layers of the
epidermis
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melanocyte and its associated group of approximately 36 keratinocytes
is known as an epidermal melanin unit (Fitzpatrick and Breathnacn, 1963).
Within the melanocytes melanin is produced in specialised
cytoplasmic organelles known as melanosomes; this was first
demonstrated by Seiji £t al. (1961) who were able to separate the
subcellular components of the melanocyte by sucrose gradient
ultracentrifugation. The enzyme tyrosinase is produced by the
ribosomes of the melanocyte, as shown by the studies of Wellings and
Siegel (1963). It is then transported through the endoplasmic
reticulum (ER) to the Golgi system. From this area, or from the
smooth ER, tyrosinase-containing vesicles bud off to form the ultra-
structural precursor of the melanosome (Seiji and Iwashita, 1965;
Hunter e_t al. , 1970). Drochmans (1967) studied high resolution
pictures of melanosomes and deduced that the first stage in
formation of the melanosomes was the deposition of a protein matrix,
composed of coiled filaments. Cross-linking of these filaments
was thought to be responsible for the transverse striations visible
in the micrographs. After formation of the protein matrix
(possibly tyrosinase units or tyrosinase linked with a structural
protein), melanin deposition gradually occurs, and the pigment
accumulates on the inner membranes obscuring the characteristic
periodicity (lOoA) of the structure. Finally the organelle
becomes a uniformly dense particle without discernible internal
structure. The fully melanised melanosome appears under the
electron microscope as a cigar-shaped, electron-dense organelle
about 0*4 - 1-2 pm along its major axis, without obvious periodicity
6.
(Hunter, 1977).
In the epidermis the melanosomes are passed from the melanocytes
to their neighbouring keratinocytes by means of the melanocyte's
dendritic processes (Cruickshank and Harcourt, 1964). The mechanism
by which this occurs is not fully understood; originally it was
thought that the melanosomes were injected into the keratinocytes,
but it is possible that the keratinocytes phagocytose the tips of
the dendrites. The melanosomes within the keratinocytes are seen
to occur either as individual membrane-bound particles, or as
aggregates of two or more particles within membrane-limited vesicles
containing lysosomal enzymes (Szabo et al. , 1969). Aggregated
melanosomes within keratinocytes undergo gradual degradation into
smaller electron-dense particles. The aggregation and degradation
of melanosomes within keratinocytes is a size-dependent phenomenon
since large single melanosomes do not appear to be broken down in
this way. Wolff and Konrad (1972, 1973) have demonstrated this
size-dependent complexing of melanosomes both experimentally (using
latex beads in guinea-pig skin) and in human pigmentary disorders.
Particles of 0*1 pm tended to be complexed whilst those with a
diameter of 0-8 pm were not. Zaynoun and coworkers (1977) con¬
firmed the size-dependence of melanosome aggregation in their
studies of pigmentation induced by topical psoralens and coal tar.
Human skin contains around 2000 melanocytes per mm^ in the
face and genital regions, whereas the rest of the body has a density
of around 1000 per mm2 (Szabo et a]L. , 1969). There is no significant
difference in the number of melanocytes per area of skin from one
racial group to another (Billingham, 1949). Shades of brown-black
pigmentation of skin, therefore, depend on factors other than
simply the number of melanin-producing cells in the skin. There
are fewer melanosomes in the melanocytes and keratinocytes of
Caucasoids and Mongoloids than in those of Negroids. Of those
present in the melanocyte most are in stages I, II and III of
development (Fig.1.2), and are not fully melanised. Those in the
keratinocytes are fully melanised but tend to be small and grouped
in membrane-limited organelles to form 'melanosome complexes'.
In the skin of Negroids and Australian aborigines there are more
melanosomes in the melanocytes and keratinocytes than in Caucasoids
and a high proportion of melanosomes are in the final stage of
development. Most of the melanosomes in the keratinocytes appear
disposed individually rather than in complexes (Szabo et: al. , 1969)
Melanin pigmentation of human skin can be divided into constit
utive and facultative skin colour (Quevedo et al., 1974). Constit
utive skin colour is genetically determined, and is generally taken
to be the degree of pigmentation found in those parts of the body
habitually shielded from light, although true constitutive skin
colour may only be seen in the newborn infant. Facultative skin
colour is the increase in melanin pigmentation brought about by
external influences, mainly exposure to ultraviolet radiation (UVR)















FIGURE 1.2 The epidermal melanin unit in caucasoid and negroid
skin
occurring in pregnancy and Addison's disease is another type of
facultative colour change. Stimuli causing facultative colour
changes may interact as, for example, during alterations in
endocrine balance (such as those seen in pregnancy), which may
increase the response of human skin to UVR. The changes in
pigmentation provoked by UVR can be divided into immediate tanning,
occurring within minutes of exposure to UVR and disappearing
rapidly, and delayed tanning, developing 48-72 hours after expo¬
sure. Immediate tanning is thought to involve a number of fac¬
tors: a rapid transfer of melanosomes from the centre of the
melanocytes to the dendrites, and from the dendrites of the
melanocytes to the keratinocytes, by some system involving micro¬
filaments and microtubules, rapid redistribution of melanosomes
within keratinocytes, and temporary oxidation of melanosomes to a
darker form (Quevedo et al_. , 1974). Delayed tanning is more
complicated, the changes occurring being more numerous. These
are thought to include:-
1) an increase in the number of functional melanocytes due to
proliferation of melanocytes and possibly activation of dormant
melanocytes (Rosdahl, 1978),
2) hypertrophy of melanocytes with increased arborization of
dendrites,
3) an increase in melanosome synthesis (Zaynoun et al., 1977),
4) an increase in the rate of melanogenesis within the melanosomes
5) an increase in transfer of melanosomes from melanocytes to
keratinocytes,
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6) activation of tyrosinase by a direct effect of UVR on the
tyrosinase - inhibiting sulphydryl compounds in the epidermis,
such as glutathione (Daniels and Johnson, 1974; Jimbow et al. , 1974;
Quevedo et al., 1974).
While the most effective stimulus to melanin production is
exposure to short wave UVR (290-320 nm), long wave UVR and even
visible light (320-700 nm) can also stimulate melanogenesis to a
much lesser extent.
Hormones can also exert a marked influence on the melanin
pigmentation of human skin, although a physiological role seems
unlikely. Administration ofoC-melanocyte stimulating hormone
(oC-MSH) to human subjects, in pharmacological doses, has been shown
to result in marked hyperpigmentation of the skin (Lerner and
McGuire, 1961). Electron microscopic examination of the skin shows
increased numbers of melanosomes and highly dendritic melanocytes,
suggesting increased transport of melanosomes into keratinocytes,
although the rapid dispersion of melanosomes readily demonstrated
in fish, amphibians and reptiles has not been directly observed in
mammals (Lerner, 1971). Although certain pituitary peptide hor¬
mones, such as MSH and adrenocorticotrophic hormone (ACTH), can
influence human skin pigmentation when grossly elevated or given
in pharmacological doses, it seems unlikely that these hormones
have a significant influence on normal physiological melanin pig¬




The chemical processes leading to the formation of melanin
are subjects in which there has been considerable interest over
the past hundred years. In 1895 Bourquelot and Bertrand dis¬
covered tyrosinase in a black toadstool, Russula Nigricans. It
soon became appreciated that the enzyme was widely distributed in
the vegetable kingdom. In the early 1920s, Raper and his
colleagues carried out extensive studies on the metabolic pathway
involved in the conversion of tyrosine to melanin in plants. The
pathway originally, outlined by Raper (1928) has since been gener¬
ally accepted, although some modifications have been suggested.
Much of the melanin synthetic pathway in humans, however, remains
to be elucidated. In the early stages, eumelanins and phaeomel-
anins are derived from the amino acid tyrosine, and have, in part
a common synthetic pathway. The first two steps are catalysed
by the enzyme tyrosinase and involve the conversion of tyrosine to
dihydroxyphenylalanine (dopa), followed by the oxidation of dopa
to the orthoquinone, dopaquinone (Fig.1.3). Orthoquinones are
amongst the most reactive of organic compounds and are capable
of undergoing a number of spontaneous reactions including oxidative
polymerisation and condensation with -NH2 or -SH groups of other
molecules. The reactivity of quinone intermediates represents a
potential hazard to the cell in which they are formed, and the
cytotoxicity of tyrosine metabolites has been demonstrated (Pawelek
and Lerner, 1978). In fact, any phenol compound represents a










FIGURE 1.3 Conversion of tyrosine to dopaquinone by the action
of tyrosinase
the cell and subsequent metabolism with generation of potentially-
damaging quinones. Pigment production, therefore, may be seen
as a detoxification mechanism by which highly reactive quinones
are converted to inert polymers by a series of spontaneous reactions
The enzyme or enzymes involved in the conversion of tyrosine
to dopaquinone have long been the subject of some controversy.
Evidence has been produced for the involvement of two separate
enzymes; peroxidase to catalyse the conversion of tyrosine to
dopa and dopa oxidase to catalyse the oxidation of dopa to dopa¬
quinone (Okun et al. , 1973). More recent studies have, however,
provided further evidence for the existence of a true tyrosinase
in mammalian melanocytes, capable of catalysing both reactions
(Hearing and Ekel, 1975; Smith and Swan, 1976). Copper has been
reported to be an essential part of the tyrosinase molecule, and
tyrosinase activity can be inhibited by substances which bind
copper (Lerner et al., 1950). Tyrosinase is the only known
enzyme involved in melanin synthesis. Once dopaquinone has been
produced by the action of this enzyme, its reactivity causes the
subsequent steps in the pathway to occur spontaneously. The
further steps in eumelanin synthesis have been largely worked out
by Raper and Mason (Raper, 1928; Mason, 1948) (Fig.1.4). Dopa¬
quinone undergoes a spontaneous intramolecular cyclisation in
which the amino group of the side chain rapidly adds to the quinone
system to produce leucodopachrome. Leucodopachrome is then
oxidised to dopachrome, which undergoes rearrangement, and decarboxy
lation, to produce 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-
14.
FIGURE 1.-4 Eumelanin synthesis from dopaquinone
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carboxylic acid. Oxidation of 5,6-dihydroxyindole leads to for¬
mation of the highly reactive intermediate 5,6-indolequinone, which,
by repeated oxidative coupling gives rise to the eumelanin polymer.
Study of the chemical properties of eumelanin, however, has shown
that the process is not quite as simple as this, and it appears
that not only the indolequinone,but also all of the other quinone
and catechol intermediates can undergo polymerisation to give
different melanin products.
The synthesis of phaeomelanin, rather than eumelanin, appears
to depend solely on the presence of cysteine or glutathione
residues in the cell (Prota et al. , 1968; Ito and Prota, 1977).
Cysteine contains the reactive sulphydryl group which is able to
combine with the dopaquinone molecule at three possible sites on
the ring system to produce four different cysteinyldopa adducts.
(Fig.1.5). Three of these are produced by the addition of the
thiol group of a single cysteine residue to the 2, 5 or 6 position
of the dopaquinone ring system. The fourth cysteinyldopa arises
by the addition of two cysteine molecules to the dopaquinone ring
in the 2 and 5 positions. The major product of the addition of
cysteine to dopaquinone is 5-S-CD, which makes up approximately
75 percent of the cysteinyldopas formed by this reaction (Prota
et al., 1968; Ito and Prota, 1977). This molecule is consequently
the main building stone for the phaeomelanins, and for the tricho-
chromes, a group of pigments found in red or yellow hair or feathers.
5-S-CD can also be produced by the reaction of dopaquinone with



















FIGURE 1.5 The cysteinyldopas produced on reaction of cysteine
and dopaquinone
glutathionedopa, with ^-glutamyl transferase and a peptidase, to
form cysteinyldopa (Agrup et al., 1975g) (Fig.1.6). Enzymatic
oxidation of 5-S-CD in vitro in the presence of catalytic amounts
of dopa has been shown to produce a red/brown polymer resembling
naturally occurring phaeomelanins (Fattorusso et al., 1969).
Further investigation has led to elucidation of part of the
phaeomelanin and trichochrome synthetic pathways (Prota, 1980)
(Fig.1.7). Enzymatic oxidation of 5-S-CD in the presence of dopa
leads to the formation of 5-S-cysteinyldopaquinone. This then
undergoes intramolecular condensation to produce the cyclic
quinoneimine intermediate. Rearrangement of this molecule by a
hydrogen shift results in the production of the phenolic isomer,
or alternatively decarboxylation of the quinoneimine results in a
further benzothiazine intermediate. The later steps in tricho¬
chrome synthesis are not as yet entirely clear, although it appears
that the benzothiazine intermediates undergo oxidative dimerisation
and decarboxylation to produce the various end products. It
appears that the same benzothiazine intermediates are involved in
the synthesis of the high molecular mass phaeomelanins, although


























1.7 Phaeomelanin synthesis from dopaquinone and
cysteine
Disorders of Pigmentation
Many disorders of pigmentation have been described.. Some of
these are acquired but many are genetic or congenital. The dis¬
orders can occur at several steps in the pigmentation process,
including the differentiation of melanoblasts in the neural crest
and a number of stages in the pathway of melanin synthesis. Two
groups of pigmentary defect are of primary interest in these
studies and will be described in more detail. These are oculo¬
cutaneous albinism and melanocytic tumours, including malignant
melanoma.
Oculocutaneous albinism
Oculocutaneous albinism (OCA) is an inheritable disorder of the
pigmentary system found throughout the animal kingdom. It is
characterised by a decrease in, or a complete absence of, melanin
in the skin, hair and eyes. In man at least four distinct
varieties of albinism exist, these being tyrosinase-negative OCA
(ty-neg OCA), tyrosinase-positive OCA (ty-pos OCA), yellow mutant
albinism and Hermansky-Pudlack syndrome. All of these are in¬
herited in an autosomal recessive fashion, and can be distinguished
from one another on the basis of clinical and biochemical criteria
(Bleehen and Ebling, 1979). The most severe form of OCA is ty-neg
OCA, which may be considered the classic type of albinism in which
the affected individuals have snow-white hair, pink-white skin,
grey irides in tangential illumination, a prominent red reflex from
a completely unmelanised fundus giving a 'pink eye' appearance,
severe nystagmus and photophobia, and markedly decreased visual
22.
acuity. Brown-pigmented naevi are absent from the skin, but small
pink spots may be seen due to accumulations of non-pigmented naevus
cells.
Electron microscopic examination of hair bulbs from ty-neg OCA
patients shows melanocytes with stage I and II premelanosomes in
which the unmelanised matrix is plainly visible (Birbeck and
Barnicot, 1959; Witkop et al., 1970). Incubation in L-tyrosine
or L-dopa does not appear to result in any increased pigmentation
in the melanosomes, and there is no evidence of enzyme activity in
the Golgi apparatus or endoplasmic reticulum (Kugelman and Van Scott,
1961; Witkop et al., 1970; Witkop, 1971). Premelanosomes do not
appear to develop past Stage II. All available evidence points to
a mutation at the tyrosinase locus such that no active tyrosinase
is synthesised (Witkop et al., 1970; Witkop, 1971).
Patients with ty-pos OCA usually have some clinically detectable
pigment, although as infants these individuals are phenotypically
similar to those with ty-neg OCA. As they grow older, however,
melanin synthesis increases, although it is still at a greatly
reduced rate, and patients accumulate some pigment in the skin,
hair and eyes. The hair may become tan, yellow or even red in
colour. Photophobia and nystagmus may lessen with age as melanin
accumulates in the choroid and retinal pigment epithelium. Visual
acuity may also improve. Ultrastructural studies of hair bulbs
from these patients reveal many stage I and II premelanosomes, and
some pigmented stage III and IV melanosomes. Incubation of hair
bulbs by the method of Kugelman and Van Scott (1961), results in
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increased amounts of pigment discernible by light microscopy.
The basic defect in ty-pos OCA is unknown. Studies have
suggested several possibilities which include a defect in the
activation of tyrosinase, an intracellular inhibitor, or a defective
feedback control mechanism (Pawelek et al., 1980).
The yellow-mutant form of albinism is common among the Amish
people. Infants with this type of albinism resemble those with
ty-neg OCA at birth, but during infancy the hair acquires a yellow
tint which turns to red during childhood. Ocular symptoms improve
with age, as in ty-pos OCA. Incubation of hairbulbs from these
patients with tyrosine alone produces a negative reaction, whereas
incubation with tyrosine and cysteine produces phaeomelanin (Bleehen
and Ebling, 1979). These patients appear, therefore, to have a
reduced ability to synthesize eumelanin.
Finally, the Hermansky-Pudlack syndrome is albinism associated
with a storage disease of ceroid-like material in the reticuloendo¬
thelial system. In addition, a defect in platelet function occurs,
often causing a severe bleeding diathesis (Witkop et al., 1973).
Melanocytic tumours
During childhood the normal ratio of melanocytes to basal
epidermal cells (approximately 1:8) changes at certain sites,
with the number of melanocytes becoming too great to be accommodated
in their normal position. This proliferation of melanocytes leads
to formation of a pigmented naevus. The type of naevus arising
depends upon the position occupied by the proliferating melanocytes
(Fig.1.8). When the melanocytes simply replace basal keratinocytes
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Melanocyte
FIGURE 1.8 Various forms of pigmented naevus showing the
position of the melanocytes
(From: Muir's Textbook of Pathology)
the lesion is known as a lentigo. A focal proliferation of melano¬
cytes with formation of small nests of cells which bulge down into
the dermis is known as a junctional naevus. A combination of this
junctional activity with the movement of small packets of melanocytes
completely into the dermis results in a lesion known as a compound
pigmented naevus. The melanocytes within the dermis are termed
naevus cells, and the deeper ones usually lose their ability to
synthesize melanin. Frequently, in the early twenties, junctional
activity ceases, the naevus cells in the dermis undergo further
maturation and some fibrosis occurs, resulting in the production
of an intradermal naevus which may remain as such for life. Although
this maturation process is most often seen in the early twenties,
similar stages of melanocytic proliferation may occur later in adult
life as a result of exposure to UVR or hormonal changes. After
puberty, any pigmented naevus with junctional activity has the
potential to undergo malignant change. Histological features of
a pigmented naevus which may point to early malignant change include
a high mitotic rate, nuclear atypia, aberrant melanocytes in the
superficial dermis, the presence of excessive melanin and a
surrounding mononuclear inflammatory infiltrate.
The most malignant of skin tumours, malignant melanoma (MM)
arises from the melanocyte. Some malignant melanomata develop
from pre-existing pigmented naevi, whilst others arise de novo
from apparently clinically normal skin. The tumour may be class¬
ified into four main forms, each characterised by distinctive
clinical and histological features; lentigo maligna melanoma (LMM),
superficial spreading melanoma (SSM), acral lentiginous melanoma (ALM)
and nodular melanoma (NM) (McGovern, 1970; Reed, 1976). The first
three types are characterised by a preceding in situ horizontal
growth phase from which an invasive melanoma develops. In NM
there appears to be no horizontal phase. NM carries the worst
prognosis of the various forms of MM, the best prognosis being in
LMM. SSM and ALM give similar intermediate prognoses. SSM is
the most commonly seen form of MM.
The prognosis for patients with primary MM is related to the
depth of invasion of the primary tumour in the dermis at the time
of its removal, and this may be assessed by the methods of Clark et al.
(1969) or Breslow (1970). The method of Clark involves staging
the lesion according to the level of invasion in the skin. In situ
epidermal lesions are level I. Level II lesions are confined to
the loose papillary dermis. In level III, the tumour forms a
plaque at the junction of the loose papillary dermis and dense
reticular dermis. In level IV there is invasion of the reticular
dermis, and in level V there is involvement of the subcutaneous fat.
The method of Breslow involves measurement of the maximal thickness
of the lesion from the granular layer of the epidermis to the deep¬
est point of invasion, by means of an ocular micrometer. Both of
these methods are of value in assessing the prognosis in patients
following surgical removal of a primary tumour. Other features
which correlate with prognosis include histogenetic type of melanoma,
as previously described, extent of ulceration, mitotic rate, and
local invasion of lymphatics (Pondes et al., 1981). The tumour
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spreads both locally by direct invasion of the surrounding skin,
by the lymphatics to local lymph nodes, and distally to other
tissues via the lymphatics and blood. These are mainly liver,
brain, lungs, bowel and bone marrow.
MM can be staged according to the extent of spread of the
tumour. The most widely used staging system for MM involves
three basic stages:
I - localised primary tumour
IA - localised recurrence (local satellites)
II - metastases to regional lymph nodes or intransit metastases
III - disseminated melanoma
(McNeer and Das Gupta, 1979).
Prognosis worsens as extent of spread of tumour increases.
Clinical features suggesting that a pigmented naevus or melanoma
in situ has undergone malignant change include itching, alteration
in colour, change in size, bleeding, ulceration and development of
satellite lesions. Such change in character of a pigmented lesion
in an adult warrant its excision and examination.
Treatment of primary MM at present is by wide surgical excision,
perhaps in conjunction with removal of local lymph nodes.
As far as treatment of secondary MM is concerned, there are a
number of choices depending on the circumstances of the individual
patient. In asymptomatic patients, those who are terminally ill,
or those of an advanced age, often no treatment is given. Surgical
removal of the secondary tumour may be performed in situations in
which the lesions are easily accessible and limited in amount, and
in patients in whom the operation can be performed safely. Irradia¬
tion is often used in patients with advanced melanoma at particular
sites in the body, including bone and brain metastases and lesions
located in the skin, subcutaneous tissues or lymph nodes. Effective
chemotherapy for melanoma metastases is not currently available, with
those drugs in current use providing a very poor response (Balch
and Milton, 1985).
Recent epidemiological studies of MM in various parts of the
world have demonstrated a rapid rise in the incidence of this tumour
in white-skinned races (Mackie, 1983). The most rapid rate of
increase, in the different areas studied, has been noted in Arizona,
where the incidence of melanoma quadrupled in the period 1969-78
from 6*5 to 27-2 per 100000 population per year. It was noted that
this increased incidence applied exclusively to those of Northern
European descent. Studies from both Queensland, which has the
highest recorded incidence of MM (32*7 per 100000 per year, in 1977),
and North America, suggest that there is a higher incidence of
melanoma in that proportion of the population who are of Celtic
descent (Lane Brown, 1971). Indeed there is evidence that individ¬
uals from Scotland and Ireland who emigrated to the sunnier climates
of Queensland and North America, and their descendants, have a
higher incidence of cutaneous MM than other European immigrants.
Study of the Scottish population in its native environment has
indicated that the incidence of MM may also be increasing but had
still only reached a level of approximately 5*1 per 100000 per year
in 1979 (Mackie and Hunter, 1982). If the genotypes of the
affected Australians and the Scottish population are indeed similar,
it would appear that environmental factors in Queensland have in¬
creased the current incidence of MM by a factor of 5 or 6.
There is considerable evidence that cumulative total lifetime
sun exposure plays a significant role in the aetiology of LMM
(McGovern et al. , 1980). Intermittent sun exposure and episodes
of burning may be more important causes of SSM and NM (Mackie and
Aitchison, 1982).
The Scottish Melanoma Group was formed in 1978 with the specific
aim of ensuring registration and proper documentation of all patients
operated on for removal of a primary cutaneous melanoma, and following
these patients from registration until death to look at changes in
the patterns of the disease with time. Scotland is a particularly
appropriate area for epidemiological study, for various reasons.
The population is a remarkably static one; there is still con¬
siderable genetic homogeneity no longer found in many other parts
of the world, especially in the USA, and, as it is a small country,
information can be readily obtained from all parts.
In a study of South-East Scotland from 1961-76 a ratio of two
females to every one male with MM in Scotland was found, in common
with findings in other countries with a low incidence of the disease
(Pondes et al. , 1981). Again in common with other studies the most
frequently found tumour was SSM on the lower limbs of females. The
prognosis appeared to be better in females than in males. The
thickness of the primary lesion was found to be the best prognostic
index, with the 5 year survival rate ranging from 97 percent for
patients with tumours less than 0*5 mm deep, to 38 percent for those
with tumours thicker than 3-5 mm. It was concluded that better
survival figures were more likely to be achieved by earlier diagnosis
and treatment of the tumour than by any other means, and that in
general the most effective way of achieving this would be through
better education of both doctors and the public, to teach them to
recognise the early signs of possible malignant change.
Tumour Markers for Malignant Melanoma
The treatment of malignant disease has improved in the last
few decades, an important part of the management being the monitoring
of patients after primary diagnosis to assess prognosis and detect
recurrence as early as possible. To this end much research is
being carried out to find biochemical markers which will give the
clinician information, above and beyond clinical signs and image
intensifying procedures, about the state of the patient's disease.
The unique nature of the chemistry of the melanocyte suggests
that there may be substances produced specifically by this cell
which may be of use in the detection of MM. In the melanin
synthesis pathway there are several intermediates which have been
examined as possible tumour markers. The first two steps in
melanin synthesis alone provide tyrosine, tyrosinase, dopa and
dopaquinone as possibilities. Tyrosine is not found exclusively
in melanocytes, being involved in general protein metabolism, so
is of no value in this respect. Tyrosinase activity, on the other
hand, has been detected in the serum of patients with MM in all but
the earliest stages of the disease (Burnett, 1975). Nishioka et al.,
(1979) have found significantly higher tyrosinase activity in sera
from MM patients compared with controls and patients with other
malignancies. Chen and Chavin (1979), however, found increased
serum tyrosinase activity in not only MM but also in many other
malignant states, including breast cancer. It has been suggested
that the apparent increased tyrosinase activity, measured as
oxidation of substrate, may be due to increased non-specific
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oxidation and may not reflect tyrosinase activity at all (Rorsman
et al., 1983).
Dopa, like tyrosine, is also not found exclusively in melanocytes,
being produced by the action of tyrosine hydroxylase in the nervous
system and adrenals as well as by the action of tyrosinase in the
melanocytes. Increased serum dopa levels have, however, been
demonstrated in some patients with advanced metastatic melanoma
(Hansson et al., 1978). A number of dopa metabolites have been
studied, and reports have appeared of increased excretion of dopa¬
mine, dopac (dihydroxyphenylacetic acid) and homovanillic aqid in
the urine of some patients with MM. Another dopa metabolite,
vanillactic acid, has also been observed in the urine of patients
with melanoma and is considered by some to be a good indicator of
metastatic disease (Duchon et al., 1967; Banda et al., 1980).
Dopaquinone, because of its highly reactive nature, is not
readily detectable. One of the reactions which it may undergo,
however, is intramolecular cyclization resulting in the indolic
precursors of eumelanin. The Thormahlen test, which is used to
detect indole conjugates, has been used in the screening of urines
from patients suspected of having metastatic melanoma (Duchon and
Pechan, 1963). It appears that the finding of a continuously
increasing excretion of these indolic compounds in the urine is
always indicative of progression of the disease, irrespective of
the absolute urinary levels found. Matous et al. (1980) found
that in many cases an increase in Thormahlen-positive compounds
was seen prior to the diagnosis of metastatic disease on the basis
of clinical signs. The instability of these compounds, however,
appears to limit the value of this method, and other workers have
had less success with it (Haberman et al., 1976).
When cysteine is present in the melanocyte, dopaquinone is
channelled into the phaeomelanin pathway by way of cysteinyldopa
formation. It was the work of Rorsman and his group in Sweden
which first demonstrated the presence of 5-S-CD and related com¬
pounds in melanomas and in the urine of patients with metastatic
melanoma (Agrup et al., 1977a). The compounds which have been
identified include 5-S, 2-S and 6-S-cysteinyldopa, 2,5-S,
S-dicysteinyldopa, 4 O-methyl derivatives of 5-S-CD and 2-S-CD,
and the trichochromes B and C (Agrup et al^. , 1976a; Prota et al. ,
1977). 5-S-CD has also been shown to be present in the urine of
normal healthy subjects (Agrup et al., 1975b).
5-S-CD appears to be the most specific product of the melano¬
cytes which has been studied, and as such has attracted attention
as a marker for melanogenesis. Exposure to sunlight, a known
stimulus to melanogenesis, has been shown to increase urinary
excretion of 5-S-CD, thus demonstrating the ability of 5-S-CD to
reflect the metabolic activity of the melanocyte (Rorsman et al.,
1976; Nixon, 1978). It was this property which induced Rorsman1s
group to look at this melanin precursor as a possible marker for MM.
Methods that have been developed for the detection of 5-S-CD
in urine, blood and tissues include ion-exchange chromatography
combined with colorimetric detection, fluorimetry, gas chromatography
mass spectrometry and high-performance liquid chromatography with
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electrochemical detection (Rorsman et al. , 1973a,b; Banda et al.,
1974; Agrup et al., 1976a; Blois and Banda, 1976; Banda et al.,
1977; Hansson et al., 1978).
The fluorimetric assay developed by Rorsman et al. (1973a,b)
has been used in several studies of urinary 5-S-CD levels. Studies
of urinary excretion in normal healthy individuals and in patients
with primary or secondary melanoma have provided evidence for the
value of 5-S-CD in MM (Agrup et al., 1975a; Agrup et al., 1977a;
Agrup et al., 1979a).
A five year study of 571 melanoma patients showed that 60 percent
of patients with metastatic melanoma had raised urinary excretion
of 5-S-CD, whereas 90 percent of those patients who did not develop
secondaries had excretion rates within the reference range determined
in healthy subjects (Agrup et al., 1979a). There were a number of
patients, however, who were found to have normal urinary 5-S-CD
excretion despite the development of metastatic disease. There
did not appear to be any single explanation for this finding,
although in some cases the secondary tumour tissue was found to be
non-pigmented. However, these findings demonstrated that a normal
urinary 5-S-CD level does not preclude the existence of metastatic
disease. A number of the patients in this study were also found
to have raised 5-S-CD levels whilst apparently remaining disease
free, according to clinical criteria. However, these patients
all developed metastases within 14 months of detection of a high
urinary 5-S-CD level. There was a significant positive correlation
between survival time and urinary 5-S-CD levels in this study;
only one patient with a high value survived for more than two years.
In patients with no clinical signs of metastases who were followed
up for two years, urinary 5-S-CD levels were similar to those in
healthy individuals. The results of this study suggested, therefore,
that measurement of urinary 5-S-CD in melanoma patients could be of
value in determining the prognosis of a patient, and, in some cases
in detecting metastatic disease earlier than the usual clinical
investigations. However, the method did appear to have limitations,
the most important being the percentage of patients who failed to
develop raised urinary 5-S-CD levels despite the presence of
metastatic disease. 5-S-CD levels were also shown to rise in
response to exposure of the patient to sunlight, and in these cases
the raised excretion of 5-S-CD was frequently as great as in
patients with MM (Rorsman et_ al., 1976). For this reason the
estimation of urinary 5-S-CD was performed, in Lund, only during
the months of September to April, thereby missing out the effects
of the summer sunshine.
The experience of Nixon (1978) in Brisbane also demonstrated
the significance of UVR-induced increases in 5-S-CD excretion in a
sunny climate. A study of 5-S-CD excretion in normal healthy
subjects in response to a mild erythema dose of sun irradiation
was carried out to determine whether it might be feasible to set
'normal limits' for 5-S-CD excretion under Australian conditions.
However, increases in excretion of 5-S-CD in response to sunlight
were found to be so great as to prevent the determination of useful
limits which could be used to differentiate increased 5-S-CD excretion
after sun exposure from increased excretion in melanoma. The
results, in fact, demonstrated that it was possible for a person
of 'Celtic' complexion to achieve urinary 5-S-CD levels well above
those of an individual with widespread metastatic melanoma, in
response to frequent small doses of sun irradiation. It was
concluded that this test could only be of use in a particularly
sunny climate if patients could avoid exposure to sunlight for
several weeks before the estimation of 5-S-CD. The results of
the study of Rorsman et al., (1976), which led them to carry out
5-S-CD estimations only between September and April, demonstrated
that even in very much less sunny climates the influence of UVR
on 5-S-CD excretion may be quite considerable. This is obviously
of major importance in the use of this test in MM.
In more recent years Rorsman's group have developed a high-
performance liquid chromatography system for measurement of serum
5-S-CD (Hansson et al., 1978; Hansson et al., 1979a). This system
is much more sensitive than the fluorimetric method used previously
which was insufficiently sensitive to detect 5-S-CD in the serum
of normal individuals. Only very limited reports of studies in
serum have yet appeared in the literature, although there is some
indication that serum 5-S-CD levels were higher in 7 melanoma
patients than in healthy individuals (Hansson et al., 1978).
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Aims
The aims of this work were to set up a method for the
detection and measurement of 5-S-CD in plasma and to use it to
study:-
1) plasma 5-S-CD levels in normal healthy individuals and,
2) the influence of the Edinburgh climate on these
3) the effect of artificial UVR on plasma 5-S-CD levels
4) the influence of skin and hair pigmentation, both normal
and abnormal, on plasma 5-S-CD
5) the handling of 5-S-CD by the liver and kidneys
6) plasma 5-S-CD levels in patients with MM and other tumours,
with particular emphasis on melanoma patients being followed






Chemicals and solvents were obtained from a variety of commercial
sources and were of analytical grade or better. A full list of
chemicals and suppliers is given in Appendix I.
Buffers





High-performance liquid chromatography (HPLC) is similar to
gas chromatography (GC) in many respects, the important difference
being the use of a liquid mobile phase in place of a gaseous one.
HPLC complements GC in that it is of considerable use in the separ¬
ation of compounds which cannot be easily volatilised, and is of
particular value in the separation of compounds which are of high
molecular mass, high polarity, or which are thermally unstable or
tend to ionise in solution.
The increased viscosity of liquids as compared to gases means
that in order to produce a similar flow through the system, the
mobile phase in HPLC must be pumped at something like 20 to 100
times greater pressure than the mobile phase in GC. The high
pressure in the system is produced by the pump, and pressures of
300 to 3000 psi are normally used.
The sample for analysis is small, and is injected directly by
syringe or valve on to the column. Columns too are small, being
typically 5mm in diameter and 10 to 25 cm in length. They are
packed with highly specialised column packings with a uniform
particle size of 5 to 10 pm.
Reverse-phase chromatography is the most commonly used HPLC
technique. In this type of system the stationary phase is usually
a hydrophobic bonded phase, such as octadecylsilane. The mobile
phases are usually polar solvents such as water and mixtures of
water and organise solvents. The retention of a solute is generally
based upon its hydrophobic character, with polar solutes preferring
the polar mobile phase and eluting before the non-polar components
which are retained by the hydrophobic stationary phase.
Reverse-phase ion-pair chromatography is of use in the separ¬
ation of ionisable substances which are eluted rapidly and are not
well separated by conventional reverse-phase systems. This type
of chromatography uses the same mobile and stationary phases as
regular reverse-phase techniques, but with the addition of an
ion-pairing agent to the mobile phase. This agent is of opposite
charge to the solutes of interest, and pairs with the solute ion
to form an electrically neutral hydrophobic ion pair. This ion
pair is retained by the stationary phase to a much greater extent
than the solute ion alone, resulting in greater resolution of similar
compounds. Ion-pairing has been employed in. the studies described
here, the agent being methanesulphonic acid.
The eluate from the column consists of a sequence of solute
zones, separated with varying degrees of resolution, which pass
through the detector. In an electrochemical detector, such as the
one used in these studies, the solute zones pass into a very low
volume thin-layer cell in which there is a carbon electrode held
at a fixed potential. If the potential is greater than that
required for electrolysis of the analyte, a measurable charge passes
from the electrode to the analyte (or vice versa), with the resulting
current being directly proportional to the concentration of solute
present. Therefore, as the concentration of solute passing through
the cell rises or falls the electrolysis current proportionately
follows these changes. The current, as a function of time, is
amplified and sent to the recorder to yield the chromatogram.
(b) HPLC system used in these studies
The HPLC apparatus consisted of an Altex model 110A peristalti
pump (Altex Scientific Inc., Berkeley, Calif., USA), a Rheodyne
model 7125% sample injector with a 50 pi sample loop (Rheodyne Inc.,
Cotati, Calif., USA), and a BAS amperometric detector, model LC-4A
with glassy carbon electrode (Bioanalytical Systems Inc., West
Lafayette, Ind., USA). The detector cell was operated at +0-75V
versus an Ag/AgCl reference electrode. The column was stainless
steel (250 x 5 mm) packed with ODS-hypersil, C18 reverse-phase
packing material, 5pm particle size (Shandon Southern Products,
Ltd., Runcorn, Cheshire, UK). The column was packed by an upward
slurry technique. The system was run at ambient temperature (20°C
The mobile phase consisted of methanesulphonic acid, 60 mmol/1, as
ion pairing agent, and orthophosphoric acid, 30 mmol/1, in water
purified by the Elgastat Spectrum reverse osmosis system (Elga
Group, Lane End, Bucks., UK). The mobile phase was thoroughly
degassed under vacuum before use.




FIGURE 2.1 The HPLC system used in'these studies
Preparation of standards
(a) Synthesis
5-S-L-cysteinyl-L-dopa and 5-S-D-cysteinyl-L-dopa were prepared
by the reaction of L-dopa with L-cysteine or D-cysteine, respectively,
in the presence of mushroom tyrosinase. The source of these chem¬
icals is given in Appendix I.
lOmg L-dopa and 12mg cysteine (D or L) were dissolved in 6ml
Sorensens phosphate buffer, 0"5M, pH 6-5 (Appendix II). 3-75mg
tyrosinase was. dissolved in 2ml of the same buffer. The two
solutions were mixed, and kept stirring vigorously for lh at room
temperature (20°C). The time course of the reaction, in terms of
appearance of 5-S-CD and disappearance of dopa, is shown in Fig.2.2.
The reaction was stopped after Ih by the addition of 6M HC1 to
take the solution to pH 1. The final product of the reaction bet¬
ween L-dopa and L-cysteine, when analysed using HPLC, was seen to
contain 6 peaks, the largest of which, with the longest retention
time was found to co-chromatograph with authentic 5-S-L-cysteinyl-
L-dopa (kindly donated by Professor Hans Rorsman). Fig.2.3 shows
the chromatogram of the final reaction product and identifies the
peak thought to represent 5-S-CD (peak X).
The final product of the reaction between L-dopa and D-cysteine
was similar to that in Fig.2.3, on HPLC analysis.
(b) Purification of reaction products
The reaction products were separated using ion-exchange
chromatography. A Quickfit column (1 x 25 cm) was packed with
AG50W-X8 ion exchange resin (200-400 mesh size, H+ form). The
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FIGURE 2.2 Time course of the reaction between cysteine
and dopa in the presence of tyrosinase, in
phosphate buffer 0*5M, pH 6*5 at 20°C
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X
FIGURE 2.3 HPLC chromatogram of final product of reaction
between cysteine and dopa in the presence of
tyrosinase
Peak X thought to represent 5-S-CD
resin was equilibrated with 0-1M HC1. The final reaction mixture
was applied to the column and washed through with 20ml of 0*5M HC1
at a rate of 30-40 ml/h. Elution was performed with 3M HC1 at a
rate of 30-40 ml/h. 5ml fractions were collected from the column
and analysed by HPLC. The ion-exchange profile for the reaction
product of L-dopa and L-cysteine is given in Fig.2.4, where fraction
number is plotted against the height of the 6 product peaks seen on
HPLC. A similar ion-exchange profile was obtained for the reaction
product of L-dopa and D-cysteine. In both cases, the fractions
containing the largest amounts of peak X, thought to be the 5-S-CD
product, were pooled and taken to dryness at 37°C in a rotary evap¬
orator. Complete dryness was achieved under vacuum in the presence
of solid NaOH. The product was redissolved in 3ml of 2M HC1.
A second ion-exchange step was performed to further separate
the 5-S-CD product from contaminants. A Quickfit column (1 x 20 cm)
was packed with AG50W-X8 resin (200-400 mesh size, H+form) and the
resin equilibrated with 0*1M HC1. The redissolved product of the
first ion-exchange step was applied to the column. The column was
eluted with 2M HC1 at a flow rate of 30-40 ml/h. 5ml fractions
were collected and analysed by HPLC. Fig.2.5 shows the fraction
number plotted against the height of peak X in each fraction.
This peak was not contaminated by measurable amounts of any of the
other reaction products, which were seen to elute in earlier fractions.
Again, the ion-exchange profile for the D-product was similar. The
peak fractions in each case were pooled, and 2ml portions of the




FIGURE 2.4 Ion-exchange profile of product of reaction
between L-cysteine and L-dopa from a 25cm
column of AG50W-X8 ion-exchange resin eluted
with 3M HC1 at a flow rate of 40 ml/h
Peak X thought to represent 5-S-CD
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FIGURE 2.5 Ion-exchange profile of pooled fractions 45 - 70
(from ion-exchange step 1) from a 20cm column of
AG50W-X8 ion-exchange resin eluted with 2M HC1
at a flow rate of 40 ml/h, showing presence of
one product only between fractions 70 and 160
(peak X)
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(c) Identification of products
The final products of these purifications were subjected to a
number of procedures in which their properties were compared to
those of authentic 5-S-L-cysteinyl-L-dopa (authentic 5-S-D-cysteinyl-
L-dopa was not available).
(i) Fluorimetry
The fluorimetric assay used was that developed by Rorsman et al.
(1973a) for the measurement of 5-S-CD. The measurements were per¬
formed on an Aminco SPF 125S spectrophotofluorimeter (American
Instrument Co., Maryland, USA). The purified reaction product
was diluted 1 in 100 with distilled water and taken through the
fluorimetric procedure. Emission and excitation spectra were
obtained for each product, and are shown in Fig.2.6. Maximum
excitation was seen at 315-320 nm for both products, and maximum
emission occurred at 415 nm. Comparison with authentic 5-S-L-
cysteinyl-L-dopa showed similar excitation and emission spectra.
Fluorimetric analysis of the reaction substrates, cysteine
and dopa, showed minimal fluorescence under the conditions of
study, and analysis of sequential samples from the reaction mixture
during the course of the reaction demonstrated an increase in
fluorescence with time as 5-S-CD was formed.
(ii) Ultraviolet absorbance
The ultraviolet absorption spectra of the reaction products
were examined on a Pye Unicam SP8-100 spectrophotometer (Pye Unicam,
Cambridge, UK). The spectra obtained are shown in Fig.2.7.







FIGURE 2.6 Fluorimetric excitation and emission spectra of
purified products of reaction between L- or D-




FIGURE 2.7 UV absorption spectra of purified products of
reaction between L- or D-cysteine and L-dopa,
thought to represent the L and D forms of 5-S-CD
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FIGURE 2.8 Second order derivatives of UV absorption spectra
of the purified reaction products thought to be
the L and D forms of 5-S-CD
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and are shown in Fig.2.8. The absorption characteristics of the
reaction products were very similar to those obtained for authentic
5-S-L-cysteinyl-L-dopa, and to those published by Agrup et al. (1976b).
Strong absorption maxima were observed at 292 and 255 nm for both
products.
The concentrations of the two cysteinyldopas. in the final
solutions could be calculated from the absorbance data, using the
equation c = A/^ x 1, where c is the concentration (mol/1), A is
the absorbance at 292 nm, £, is the molar extinction coefficient
( £, = 2800, -Agrup et al., 1983), and 1 is the light path length (cm).
The concentrations of the two products were found to be 50pg/ml and
40pg/ml for the L form and D form, respectively.
(iii) HPLC
The HPLC system described on page 42 was used in the analysis
of the purified reaction products. The chromatograms obtained
are shown in Fig.2.9. In each case there was one peak with vir¬
tually undetectable levels of contamination from other products.
The product thought to be 5-S-L-cysteinyl-L-dopa was found to co-
chromatograph with authentic standard material. The product thought
to be 5-S-D-cysteinyl-L-dopa was found to be well separated from the












FIGURE 2.9 HPLC chromatograms of purified products of reaction
between L- or D-cysteine and L-dopa, thought to be
the L and D forms of 5-S-CD
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Preparation of plasma samples
(a) Activation of aluminium oxide
lOOg aluminium oxide (A1 0 ) was heated in 500ml 2M HC1 at
o
90 C for 45 min, with continuous and rapid stirring. The A1 0
c. O
was allowed to settle and the supernatant removed and discarded.
The Al^O was was^ed twice with fresh 250ml portions of 2M HC1 at
o
70 C for 15 min, and the supernatant discarded each time. The
AlgOg was washed finally with 500ml 2M HC1 at 50°C for 10 min.
The supernatant was discarded and the Al^O^ washed approximately
20 times with fresh 200ml portions of distilled water, until a pH
of 3"4 was reached. The Al^O^ was transferred to an evaporating
dish, heated at 120°C for lh and 200°C for 2h. The activated
Al^Og was stored in a stoppered glass container.
(b) Extraction of 5-S-CD from plasma
Blood samples were taken into lithium-heparin tubes containing
dithiothreitol (final concentration 5mM) as preservative. Samples
were centrifuged at 2500 g for 10 min at 20°C, and the plasm.a
separated off using a Pasteur pipette. 2ml plasma was used for
the assay of 5-S-CD. The plasma was placed in a tube with internal
standard (5-S-D-cysteinyl-L-dopa) and mixed well. 50pl reduced
glutathione solution (0"05M) was added with 50pl ethylenediaminete-
traacetic acid solution (EDTA:0*3M, pH 7-0) and 20mg activated
Al^Og* "the tube contents mixed, and 20pl Tr.is buffer (1M, pH 8*6)
added during mixing. The tubes were placed in a vortex mixer, and
the tube contents mixed vigorously for 15 min. The tubes were
centrifuged at 3000g for 5 min at 20°C, to take down the Al^O^ and
the supernatant removed and discarded. The Al^O^ was washed three
times with 2*5ml EDTA solution (0-003M, pH 8*0). After each wash,
the tubes were centrifuged at 3000g for 5 min at 20°C, and the
supernatant discarded. 150pl perchloric acid (0-2M) was added to
the A1 0 and the tubes mixed vigorously in a vortex mixer for
^ o
1 min. After a final certrifugation at 3000g for 5 min at 20°C,
50pl of the supernatant was taken for HPLC analysis.
(c) Recovery of cysteinyldopa from plasma
A calibration curve was prepared by injecting known amounts
of standard material, both 5-S-Lcysteinyl-L-dopa (L-5-S-CD) and
5-S-D-cysteinyl-L-dopa (D-5-S-CD), made up in 0*2M perchloric acid,
directly into the HPLC system and measuring the resulting peak
heights.
Duplicate plasma samples were prepared, each 2ml in volume.
To one of these was added a known mass of each 5-S-CD standard.
Both samples were taken through the extraction procedure and analysed
by HPLC. The peak heights of the two 5-S-CDs in each sample were
noted. Percentage recovery of each 5-S-CD was calculated as
follows, if (a) is the sample with no added standards, and (b) is
the sample with added standards.
Peak height of L-5-S-CD in (a) is x
Peak height of L-5-S-CD in (b) is y
Peak height representing added L-5-S-CD is (y - x)
Mass of L-5-S-CD corresponding to a peak height of (y - x)
was read from the calibration curve, and from this the mass of
L-5-S-CD in the extract was calculated. This was compared with
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the mass of L-5-S-CD added to the plasma prior to extraction, and
the ratio of the two values gave the percentage recovery of L-5-S-CD
from the procedure. The recovery of D-5-S-CD was calculated in
the same manner, although there was, of course, no D-5-S-CD present
in the plasma to which no standard had been added.
Four pairs of duplicates were prepared for calculation of
recovery of L-5-S-CD and D-5-S-CD, and the results are given in
Table 2.1.
(d) Preservation and storage of blood samples
Storage of whole blood, serum and plasma
60ml blood was taken from a volunteer and placed in tubes as
follows:- 10ml in a plain glass tube, and the remaining 50ml in
5 10ml plastic lithium-heparin coated tubes, for the following
studies.
(i) Comparison of serum and plasma in 5-S-CD estimation
One blood sample in a glass tube, and one in a plastic lithium-
heparin tube were centrifuged at 2500g for 15 min at 20°C. Two
portions, each of 2ml, of plasma and serum were obtained, extracted
and analysed.
(ii) Overnight storage of whole blood and plasma
Two samples in lithium-heparin tubes were taken. One was
stored as whole blood overnight at 4°C, whilst the other was
centrifuged at 2500g for 15 min at 20°C, and the plasma obtained
stored at 4°C overnight. The blood sample was centrifuged, under
the same conditions, the following day, and the plasma removed.
Two portions, each of 2ml, of each plasma, were extracted and
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Table 2.1 Recovery of L-5-S-CD and D-5-S-CD from plasma
Percentage Mean percentage
recovery recovery
L-5-S-CD 50, 47, 50, 54 50
D-5-S-CD 51, 48, 57, 60 54
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analysed.
(iii) Effect of antioxidant on 5-S-CD levels in stored plasma
Two 10ml blood samples in lithium-heparin tubes had dithiothreitol
added to final concentrations of 5 and 25 mmol/1. The samples
were centrj.fuged at 2500g for 15 min at 20°C, and the plasma re¬
moved from each and stored overnight at 4°C. Two portions, each
of 2ml, of each sample were extracted and analysed.
The results of these studies are given in Table 2.2. Extrac¬
tion of 5-S-CD from plasma appeared to be slightly more efficient
than extraction from serum. In addition, the plasma samples were
easier to prepare, both in terms of time required to obtain plasma
from the samples, and in the use of plastic tubes which were less
readily broken during centrifugation. All further studies were
therefore carried out using plasma.
The mass of 5-S-CD recovered from samples stored overnight
did not seem to be affected by whether the samples were stored in
the form of whole blood or plasma or whether antioxidant was added
to the sample prior to storage for this short period of time.
Further studies of plasma storage
A 50ml pool of plasma was prepared, divided into 2ml portions,
and used in the following studies:-
(i) Two 2ml portions were immediately extracted and analysed




(d) with 5mM dithiothreitol at -20°C
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Table 2.2 Storage of whole blood, serum and plasma
Sample 5-S-CD conchi(nmol/1) Mean 5-S-CD conc*n
(nmol/1)
(i) Plasma 47, 49 48
Serum 40, .44 42
(ii) Whole blood 48, 50 49
Plasma 47, 48 47*5
(iii) Plasma plus
5mM dithiothreitol 49, 51 50
Plasma plus
25mM dithiothreitol 48, 49 48-5
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(iii) Two 2ml portions were stored for 1 week
(a) at 20°C
(b) with 5mM dithiothreitol at 20°C
(iv) As for (iii), but storage for 2 weeks
(v) As for (iii), but storage for 4 weeks
The results of these studies are given in Table 2.3. 5-S-CD
in plasma was stable for up to 4 weeks when dithiothreitol' was'
added prior to storage at -20°C.
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Identification of cysteinyldopas in plasma
(a) Co-chromatographv with standards
Plasma extracts were subjected to HPLC under varying
chromatographic conditions. Plasma extracts with added
5-S-L-cysteinyl-L-dopa were also analysed. Fig.2.10 shows the
effect of varying the pH of the mobile phase on the retention of
the plasma peak thought to represent 5-S-CD. The change in
retention of authentic 5-S-CD in response to changing pH was seen
to parallel the change in retention of the plasma peak.
Fig.2.11 shows the effect of varying the concentration of
ion-pairing agent in the mobile phase on retention of both plasma
and standard 5-S-CD peaks. Again the changes are seen to run in
parallel.
Fig. 2.12 shows examples of the co-chromatography of authentic
5-S-CD with the plasma peak thought to represent 5-S-CD.
These studies lend support to the provisional identification
of the. peak as 5-S-CD.
(b) Oxidation properties
As the electrical potential applied across a solution under¬
going analysis by electrochemical means is changed, the size of the
resulting chromatographic peaks, representing the analytes present
in the solution, will also vary, and the way in which they vary
is characteristic of each particular analyte, and dependent on its
oxidation properties. A hydrodynamic voltammogram can be constructed
for each analyte which demonstrates the way in which chromatographic
peak height varies with changing potential. The hydrodynamic
voltammogram for 5-S-CD is shown in Fig.2.13. This figure also
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FIGURE 2.10 The effect of pH of the mobile phase on retention
of 5-S-CD on a HPLC column, plotted as pH versus
capacity factor (k')
k' = V - V , where V = elution volume
r o r
V V = void volume
r o
(a) authentic 5-S-CD standard
(b) plasma peak X thought to represent 5-S-CD
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Methanesulphonic acid concn(g/l)
FIGURE 2.11 The effect of ion-pairing agent concentration of
the mobile phase on retention of 5-S-CD on a
HPLC column, plotted as concentration versus
capacity factor (k1)
(a) authentic 5-S-CD standard
(b) plasma peak X thought to represent 5-S-CD
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FIGURE 2.12 Co-chromatography of plasma extract and standard
5-S-CD in a HPLC system with mobile phase of
differing pH
a and c - plasma extract
b and d - plasma extract plus standard 5-S-CD
X = 5-S-CD peak
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Potential (V)
FIGURE 2.13 Hydrodynamic voltammogram (peak height on HPLC
chromatogram versus electrical potential applied
across solution by amperometric detector) for
standard 5-S-CD and plasma peak X
(a) standard 5-S-CD in water
(b) standard 5-S-CD in plasma
(c) plasma peak X
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shows the voltammogram obtained for 5-S-CD added to plasma, and
it can be seen that it is not identical to that obtained for
5-S-CD in water. This is probably due to interference from other
oxidisable substances present in the plasma. The figure also
shows the voltammogram for the chromatographic peak thought to
represent naturally-occurring plasma 5-S-CD, and this is seen to
be very similar to that obtained for 5-S-CD added to plasma, further
supporting the identity of this peak as 5-S-CD.
(c) Identification of other cysteinyldopas in plasma by retention
times
The identities of some of the reaction products of (2) (a),
other than 5-S-CD were deduced on the basis of elution order from
ion-exchange and HPLC columns, and the relative amounts of each
product formed, as compared with the findings of Ito and Prota (1977).
Fig. 2.14 shows the chromatogram of the final reaction product and
the likely identities of a number of the peaks.
Although this identification was largely speculative, the peaks
which were seen in plasma and seemed to correspond to the identified
reaction products were those which, in addition to 5-S-CD, were seen
to be considerably larger in plasma from some patients with metastatic
melanoma or in other situations in which elevated 5-S-CD levels were
found. Fig.2.15 demonstrates the increase in size of a number of
the peaks, seen in plasma from a patient with metastatic melanoma.
Calibration and routine use of the plasma 5-S-CD assay
(a) Construction of calibration curves





FIGURE 2.14 HPLC chromatogram of product of reaction between
cysteine and dopa in the presence of tyrosinase
















FIGURE 2.15 HPLC chromatograms of plasma extracts from a
healthy individual and a patient with stage III
melanoma showing the increase in size of a number
of plasma peaks in the melanoma patient
IS = internal standard
5 = 5-S-CD
3 and 6 = other cysteinyldopas
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and extracted as described on page 57. The extracts were analysed
by HPLC and the results used to construct calibration curves.
(Table 2.4).
Curves obtained for 5-S-CD in water and 5-S-CD in plasma were
very similar indicating that extraction of 5-S-CD from these two
media does not differ greatly and that matrix effects are insignifi¬
cant. The use of water standards in day to day calibration of the
assay was considered to be acceptable.
A set of five water standards was, therefore, prepared at con¬
centrations ranging from 1*25 to 125 ng/ml, and 2ml portions of
o
these, containing 5mM dithiothreitol, were stored at -20 C until
required. A calibration curve was constructed using these five
standards, which were extracted with each batch of samples, on every
occasion that an assay was performed.
(b) Intra- and inter-assay precision and quality control
(i) Intra-assay precision
The intra-assay precision was established by extracting and
analysing 10 portions of each of 2 plasma pools, one containing a
low and one a high concentration of 5-S-CD. The results are given
in Table 2.5.
(ii) Inter-assay precision
The inter-assay precision was established by accumulating
quality control data, based on the analysis of one sample each of
the high and low concentration pools in 23 consecutive analytical
runs. The coefficients of variation for these groups of results
are given in Table 2.6.
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Table 2.4 Construction of calibration curves
Water standards
L-5-S-CD added (ng) Ratio of peak height of L-5-S-CD
















L-5-S-CD added (ng) Ratio of peak height of L-5-S-CD































Mean 5-S-CD (nmol/1) 11*19 213*22













(iii) Quality control of the routine assay
Two plasma pools were prepared, one being at a high level of
5-S-CD, and one at a level which may be expected in healthy controls
both containing 5mM dithiothreitol. 2*5ml portions of each pool
were prepared and stored at -20°C until required. Each time an
assay was performed, a portion of each of the quality control pools
was extracted and analysed with the other samples and standards.
Results were recorded with previous quality control results.
Patients and controls
(a) Healthy volunteers
(i) Study of plasma 5-S-CD levels over a 12 hour period
The subjects involved in this study were 4 healthy volunteers,
3 males and 1 female, aged between 23 and 47 years. These subjects
had 10ml blood samples taken at hourly intervals over a period of
12h, between 9am and 9pm. The subjects had fasted from the previous
evening, but were allowed to eat normally after the first sample had
been taken.
(ii) Study of plasma 5-S-CD levels over a 12 month period
The subjects described in this study were 11 healthy volunteers,
7 males and 4 females, aged between 23 and 49 years. These volun¬
teers had 10ml blood samples taken at monthly intervals over a
period of 12 months, between January and December 1983. The sub¬
jects were all resident in Edinburgh (latitude 56°N), although
several of them had holidays abroad during the period of study.
(iii) Study of plasma 5-S-CD levels in individuals with
different skin and hair colours
The white-skinned subjects with blonde or brown hair involved
in this study were 9 of the healthy volunteers involved in the study
of seasonal variation in plasma 5-S-CD. The 8 white-skinned sub¬
jects with red hair were also healthy individuals from the Edinburgh
area. The 11 black-skinned, black-haired subjects of African
descent were resident either in Edinburgh or Birmingham (latitude
53°N). These subjects all had a single 10ml blood sample taken.
(b) Patients with oculocutaneous albinism
20 patients with oculocutaneous albinism (OCA), 10 being
tyrosinase-negative and 10 tyrosinase-positive, had 10ml blood
samples taken for estimation of plasma 5-S-CD. Of these 20
patients, the tyrosinase status of 3 was determined using a
hairbulb tyrosinase test (Kugelman and Van Scott, 1961). The
status of the remaining 17 patients was assessed by clinical means
alone, tyrosinase-positive albinos being those with coloured
irides, minimal hair pigmentation and scattered pigmented naevi,
and tyrosinase-negative albinos being those with translucent
irides, white hair, and no pigmented naevi.
(c) Patients with psoriasis undergoing treatment with UVR
The subjects studied in this investigation were patients under¬
going UV treatment for widespread psoriasis. The patients were
receiving either short-wave UVR (UVB: 280-315 nm) or photochemo-
therapy in the form of combined psoralen and long-wave UVR
(UVA: 320-400 nm), commonly called 'PUVA' (Parrish, 1981).
Psoralens are naturally-occurring, tricyclic, furocoumarin-like
compounds, some of which can be activated by UVA to elicit photo-
toxic reactions. The rationale for the use of PUVA in the treat¬
ment of psoriasis is inhibition of the increased DNA synthesis
within keratinocytes of the psoriatic lesions. This inhibition
is accomplished by a specific interaction between psoralen and
DNA molecules that involves absorption of radiant energy in the
UVA range. Absorption of photons in the UVA spectrum transforms
psoralen molecules into a photoexcited state, resulting in photo-
conjugation of psoralen with the pyrimidines of DNA and inhibition
of DNA synthesis and, therefore, cell division (Parrish et al., 1978).
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Treatment of individual patients was largely dependent on
skin type, defined in terms of the response to exposure to natural
sunlight as follows:- I - always burn, never tan; II - sometimes
burn, eventually tan; III - rarely burn, usually tan; IV - tan,
never burn.
Patients received treatment twice weekly at first, and less
frequently thereafter, although there was some variation in
frequency of treatment from one patient to another.
Patients receiving PUVA therapy were given 1*5 - 2*5 mg/kg
body weight of 8-methoxypsoralen (8-MOP), which is a derivative
of psoralen itself, and is the most commonly used in medicine
(Parrish, 1981). The administration of 8-MOP was followed, after
2h, by irradiation using a Waldmann 6001 unit containing fluorescent
tubes with an emission spectrum between 320 and 390 nm and a peak
emission of 365 nm. Patients were started with a dose of 1 to 2
2
J/cm , depending on skin type and response to a test dose, and this
2 2
was increased by 0*5 to 1 J/cm per session to a maximum of 9-5 J/cm .
Blood samples for 5-S-CD assay were taken before therapy was started,
and thereafter at approximately weekly intervals.
The UVB light source was a Theraktin UV bath, with an emission
spectrum of 270 to 310 nm, and a maximum of 290 nm. The intensity
of radiation was estimated to be 0-45 mW/cm. The initial dose
was approximately 0*15 J/cm, and this was increased by 0*05 to
0*2 J/cm per session, to a maximum of 1*35 J/cm, again depending
on skin type. Blood samples for 5-S-CD assay were taken before
therapy was started, and thereafter at approximately weekly
intervals.
The degree of pigmentation and erythema induced by the treat¬
ment, either absent, minimal or marked, was recorded for each
patient, and the times at which these responses were seen were also
recorded.
(d) Patients with psoriasis undergoing treatment with dithranol
The subjects involved in this study were 6 patients undergoing
treatment with topical dithranol (1,8 - dihydroxy - 9 - anthrone).
The mechanism of therapeutic action of dithranol in psoriasis is
thought to be due to a demonstrable interaction with DNA (Swanbeck
and Zetterberg, 1971). Dithranol often has an irritant action on
the skin resulting in erythema, and it is this property which was
of interest in this study. Oxidation of dithranol results in the
formation of products which cause discolouration of the skin which
is not related to tanning (Ponec and Hulsebosch, 1974).
The patients in this study were started on 0*1% dithranol, the
concentration being increased gradually to 0*5 or 1%, depending on
the degree of erythema produced and improvement of the psoriasis.
Patients generally received treatment daily. The presence of
erythema and its severity (minimal or marked) were noted. Patients
had blood samples taken before treatment was started, and thereafter
at approximately weekly intervals.
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(e) Patients with malignant melanoma
The clinical staging of disease in the melanoma patients
involved in these studies is as follows:-
Stage I - primary tumour alone
Stage II - local lymph node involvement + primary tumour
Stage III - metastatic spread beyond local lymph nodes
(i) Patients with primary cutaneous malignant melanoma
22 patients with histologically proven clinical stage I primary
cutaneous MM were involved in this study. There were 11 female
and 11 male patients with ages ranging from 26 to 69 years. All
had a single 10ml blood sample taken immediately before surgical
removal of the tumour.
(ii) Patients undergoing follow-up after surgery for stage I
or stage II disease
All patients seen at the melanoma follow-up clinic in the
Dermatology Dept., Royal Infirmary of Edinburgh, between January
and December, 1983, had a 10ml blood sample taken, for 5-S-CD
estimation, at each attendance.
These patients can be divided into a majority who were being
followed up after surgery for stage I MM (usually wide excision
and grafting), and a few who were being followed up after surgery
for stage II MM (usually radical block dissection of local nodes).
All of these patients were clinically disease free after their
respective surgical procedures, and attendance at the follow-up
clinic was for the purpose of assessment of their general state of
health, and investigation of possible signs of development of
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metastatic disease.
There were 88 patients in this group, 82 with stage I and 6
with stage II MM. 25 of the patients were male, and 63 female,
with ages ranging from 18 to 91 years, at the beginning of the study.
Any patient who was found to have what was considered to be a
raised plasma 5-S-CD level (greater than 20nmol/l), was recalled to
the clinic as soon as possible for a repeat blood sampling. A
repeatedly high plasma 5-S-CD level was investigated further, with
the patient being subjected to a chest X-ray and thorough clinical
examination. Where indicated, a CAT scan (computerised axial
tomography) was also performed to assess intra-abdominal lymph node
enlargement.
(iii) Patients with clinical stage III MM
There were 26 patients in this group, all with known stage III
MM at the time of study. 10 of these patients had skin or subcut¬
aneous metastases often with involvement of local lymph nodes, and
the remaining 16 had visceral metastases, with involvement of, for
instance, brain, lung or liver. There were 13 males and 13 females
in this study, with ages ranging from 26 to 77 years.
These patients had either a single 10ml blood sample taken, or
sequential samples over a number of months, for estimation of plasma
5-S-CD levels. Note was made of any treatment which the patients
were receiving at the time of sampling, and whether or not the
patients were responding to treatment. Results of liver function
tests (LFTs) were also recorded where obtainable. These included
bilirubin, alkaline phosphatase and lactate dehydrogenase.
In a few of the patients, samples of secondary tumour were
available for pigment assessment and this was carried out in the
Dept. of Pathology, University of Edinburgh. Pigmentation was
graded on a scale of 0-4, 0 being when there was no visible pigment
on either haematoxylin or eosin staining or special staining for
melanin by Masson-Fontana, and 1-4 being a subjective assessment
of level of pigmentation. All assessments were performed by
Dr. K. McLaren.
(f) Patients with non-melanoma tumours
38 patients with histologically proven .non-melanoma malignant
tumours, including breast, lung, stomach, and ovarian cancers, and
lymphoma, had single 10ml blood samples taken for plasma 5-S-CD
estimation.
10 patients with non-melanoma tumours and known metastatic
involvement of the liver had single 10ml blood samples taken for
estimation of plasma 5-S-CD. Where possible, results of standard
LFTs were also recorded.
(g) Patients with abnormal liver function
14 patients with inflammatory, rather than metastatic carcinom¬
atous, liver disease had 10ml blood samples taken for 5-S-CD estim¬
ation. 1 patient had 3 samples taken at 1 month intervals.
Standard LFTs were also performed at the time of plasma 5-S-CD
estimation.
(h) Patients with chronic renal failure
14 patients with chronic renal failure had blood samples taken
for 5-S-CD estimation. Plasma urea and creatinine levels were also
measured at the time of estimation of plasma 5-S-CD.
( i ) Patients with Parkinson's disease
One patient attending the melanoma follow-up clinic, following
removal of a stage I melanoma, who was apparently disease free, was
found to have a markedly raised plasma 5-S-CD level on 2 consecutive
occasions. This patient also had Parkinson's disease and was, at
that time, undergoing treatment with combined L-dopa and carbidopa
("Sinemet": Merck, Sharp & Dohme, Herts., UK). It was, therefore,
decided to investigate other patients with Parkinson's disease to
see if a raised plasma 5-S-CD was a common finding in these patients.
8 further patients with Parkinson's disease had 10ml blood
samples taken for estimation of plasma 5-S-CD levels. 5 of these
patients were undergoing treatment with "Sinemet", and the remaining
3 were being treated with amantadine ("Symmetrel": Geigy Pharma¬
ceuticals, Sussex, UK). It was not possible to obtain samples
from untreated Parkinson's patients.
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RESULTS
Plasma 5-S-CD levels over a 12 hour period
The results of this study are presented in Fig.3.1. There
was some variation in the mean plasma 5-S-CD concentration during
the 12h period, the lowest mean value being 4*6 nmol/1 at 1pm,
and the maximum value of 6-3 nmol/1 occurring at 4pm and 9pm.
The slight increases observed in plasma 5-S-CD mid afternoon and
evening may have been related to ingestion of meals. Comparison
of the lowest and highest values observed throughout the day by
means of an independent t-test showed these two sets of values to
be statistically significantly different (p<0*05).
Plasma 5-S-CD levels over a 12 month period
The results of this study are presented in Fig.3.2. Plasma
5-S-CD concentrations were low during the winter, but began to
rise during the spring months to reach a maximum mean value of
11-9 nmol/1 in June. Thereafter the mean concentration fell to
a minimum value in December.
The considerable variation between results from individual
subjects at any time is reflected in the large standard errors.
Comparison of the results for June and December, the highest and
lowest mean values respectively, by means of an independent t-test,
shows a statistically significant difference between these two sets
of figures (p<0-05).
Plasma 5-S-CD concentrations in the 11 healthy individuals all
of whom were resident in Edinburgh did not rise above 20 nmol/1,
even during the summer months. This figure was taken to represent
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FIGURE 3.1 Plasma 5-S-CD levels in 4 healthy individuals
over a 12h period
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FIGURE 3.2 Plasma 5-S-CD levels in 11 healthy individuals
over a 12 month period
be expected in patients being seen in clinics in and around Edinburgh.
There did not appear to be a significant rise in plasma 5-S-CD
levels from pre- to post-holiday measurements in those of the subjects
who had holidays abroad, and any change which was seen was comparable
to that seen in those subjects who stayed in Edinburgh during the
summer.
Plasma 5-S-CD levels in individuals with different skin and hair
pigmentation
The results of this study are presented in Fig.3.3. All sub¬
jects were found to have plasma 5-S-CD levels which fell within the
previously determined reference range. Statistical analysis of
the results shows that there was no significant difference between
levels in white-skinned subjects with blonde or brown hair and
levels in white-skinned subjects with red hair, or between levels
in white-skinned and black-skinned subjects (independent t-test,
p> 0*05).
Plasma 5-S-CD levels in oculocutaneous albinism
The results of this study are presented in Fig.3.4. All 20
patients were found to have plasma 5-S-CD concentrations which were
within the reference range. Statistical analysis of the results
showed that there was no significant difference between the results
from normally pigmented controls and albinos, or between results
from tyrosinase-negative and tyrosinase-positive albinos (indep¬
endent t-test, p>0*05).
The effect of exposure to UVR on plasma 5-S-CD levels in psoriatic
patients
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FIGURE 3.3 Plasma 5-S-CD levels in subjects with different
skin and hair pigmentation (individual values














FIGURE 3.4 Plasma 5-S-CD levels in normally pigmented
individuals and patients with tyrosinase-
positive and tyrosinase-negative oculocutaneous
albinism (individual values plus bar representing
mean value)
Table3.1.










W.B.(II) M.B.(IV) U.K.(Ill) J.M.(III) A.R.(III) E.T.(IV) J.C.(ii)
7.1 4.5 1.9 5.9 6.2 6.5 3.4
7.8 10.0 11.2 14.5 15.2 8.0 12.2
17.4 (223)
16.8 (147)
14.1 (176) 28.6 (234)
15.1 (194) 17.3 (173) 27.113.7 (242)12
18.020.5 (124)( 41 21.8 (143)37.7 (248) 27.8 (228)
12.8 (160)
16.1 (206)
10.5 (105) 11.6 (104)
23.114.8 (159)02 28.2.1 (186)5 17.3 (216) 18.9 (155)
8.8 (113) 11.0 (98)
5.8 (74) 7.2 (72)
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and in Fig. 3.5. All 6 of the patients treated with PUVA were
found to have increased plasma 5-S-CD levels, occurring between 5
and 20 days after treatment was started, usually between the first
and fifth treatments. Peak 5-S-CD levels, which were 2 to 5 times
the pre-treatment levels, were reached, in most cases, between 10
and 20 days after the start of the treatment. Thereafter there
was considerable individual variation in response to continuing
treatment, with levels in some patients returning to approximately
the pre-treatment value, whilst in others they continued to fluc¬
tuate throughout treatment.
UVB therapy also caused a rise in plasma 5-S-CD levels in all
6 patients studied. This rise tended to occur earlier than in the
PUVA patients. The peak 5-S-CD values were between 1*5 and 2-5
times pre-treatment values, and the rises were overall considerably
smaller than those seen in PUVA patients. The peak value tended
to occur between 2 and 10 days after the start of treatment, and
was generally followed by a return towards pre-treatment values
shortly afterwards.
The response to treatment, in terms of the rise in plasma
5-S-CD levels, was generally observed, in both groups of patients,
at a time when no tanning was as yet present, but there was often
erythema.
Plasma 5-S-CD levels in psoriatic patients undergoing treatment
with dithranol
The results of this study are presented in Table 3.3 and Fig.
3.6. Of the 6 patients studied,an increase in 5-S-CD levels was
96.
FIGURE 3.5 The effect of UVB and PUVA treatment on plasma
5-S-CD levels in psoriasis patients
Table3.3








































Days after start of treatment
FIGURE 3.6 The effect of topical dithranol treatment on
plasma 5-S-CD levels in psoriasis patients
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seen in 3. The increase in mean 5-S-CD levels seen between days
6 and 10 after the start of treatment was not statistically sig¬
nificant when compared to the mean starting level (independent
t-test, p>0*05). There did not appear to be any relationship
between erythema and 5-S-CD levels.
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Plasma 5-S-CD levels in patients with primary cutaneous malignant
melanoma
The results of this study are presented in Fig.3.7. All 22
patients were found to have plasma 5-S-CD concentrations below
20 nmol/1 which had been accepted as the upper limit of the ref¬
erence range. The mean 5-S-CD concentration in these individuals
was not significantly different from the mean in healthy controls
(independent t-test, p>0-05).
Plasma 5-S-CD levels in clinically disease-free patients during
follow-up after surgery for stage I and stage II MM
There were 88 follow-up patients in this study, and of these
4 developed confirmed metastases during the year of study; a
further 5 developed metastases in the following 8 months. The
results from these patients are presented in Table 3.4. Of the
4 patients who developed metastatic melanoma during the year of
study, in 2 the first sign of progressive disease was a raised
plasma 5-S-CD level (Fig. 3.8). In one of these patients (TI)
this rise was observed 2 months before the patient began to feel
generally unwell and the presence of liver and lung metastases was
confirmed. In the second of these patients (HI) an increase in
5-S-CD was first seen 9 months before detection of metastatic disease,
but this was followed by a return of the 5-S-CD level to within the
reference range. The level did not increase again until 8 months
later, 1 month before confirmation of the presence of liver and
lung metastases. Both of these patients died within 1 month of










FIGURE 3.7 Plasma 5-S-CD levels in healthy controls and stage
I melanoma patients (individual values plus bar
representing mean value)
Table3.4
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FIGURE 3.8 Plasma 5-S-CD levels in 2 patients (HI and TI)
over a period of 11 months during which both
patients developed stage III melanoma
The remaining 2 patients who developed metastases within the
year of study had normal plasma 5-S-CD levels at each visit to the
follow-up clinic. One of these patients (MG) had a large secondary
tumour removed from her abdomen, which was barely pigmented macros-
copically, and on histological examination was seen to have minimal
evidence of melanin production. This was the only patient in whom
metastatic tumour tissue was available for histological examination.
The other patient in this category (AS) developed liver metastases.
Of the 5 patients who developed metastases after the conclusion
of the 5-S-CD study, 2 had at some point been found to have abnormal
5-S-CD levels during the study. In one of these patients (SS) the
increased level had been seen 9 months before metastases were even¬
tually confirmed, and in the other (EM) the raised level had occurred
2 months before. The remaining 3 patients (MB, GB and DC) developed
metastases 4, 6 and 8 months respectively after the completion of
the study, but had not had raised 5-S-CD levels before the study
ended.
Of the 79 follow-up patients who had not shown clinical signs
of metastatic disease up until 20 months after the start of the study,
7 nonetheless had a raised plasma 5-S-CD level at some point during
the study. Repeat sampling from these patients, however, resulted
in the finding of normal plasma 5-S-CD concentrations, and no further
investigations were performed.
Plasma 5-S-CD levels in patients with stage III MM
The results of this study are presented in Fig.3.9, with the
values shown in the figure being the highest 5-S-CD level seen in
each of the patients involved.
15 of these 26 patients were found to have raised 5-S-CD levels,
some repeatedly, and 11 had levels which fell within the reference
range, again sometimes on more than one occasion. All of the
patients who were found to have raised plasma 5-S-CD levels at the
time of the first blood sample had consistently raised levels, if
subsequent samples were obtained. The same consistency was seen
in patients who had normal 5-S-CD levels in the presence of meta¬
static disease.
Liver function test (LFT) results were noted where available
in these patients. 10 of the 15 patients with elevated 5-S-CD
levels also had abnormal LFTs, either lactate dehydrogenase (LDH)
or alkaline phosphatase (ALP), or both (Table 3.5). The remaining
5 patients with raised 5-S-CD levels had normal LFTs. Of the 11
patients with normal 5-S-CD levels, 2 had abnormal ALP, 4 had normal
LFTs, and for the remaining 5 there was no record of LFTs at the
time of plasma 5-S—CD estimation. 67% of the patients with abnormal
5-S-CD levels, therefore, also had abnormal LFTs, whereas the propor¬
tion of patients with normal 5-S-CD levels and abnormal LFTs was
lower, being 33% of the 6 patients in whom these results were avail¬
able .
There was no evidence of impaired renal function in those patients



































FIGURE 3.9 Plasma 5-S-CD levels in 26 patients with stage
III melanoma (plotted on a log scale)
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Table 3.5 Plasma 5-S-CD and LFTs in patients with stage III
PAtient Plasma 5-S-CD LDH ALP
(nmol/1) (U/l) (U/l)
HI 950.4 815 334
AA 857.6 N N
TC 522.2 857 191
MS 332.0 N N
PS 315.0 N N
HD 288.4 3680 163
MK. 254.7 NA 154
TI 250.2 3585 900
GG 99.7 760 169
DB 83.1 475 N
CI 62.5 461 N
SF 60.9 N N
MF 39.3 4310 N
EA 27.0 601 N
PM 21.6 N N
MGr 15.0 NA KA
RR 13.7 N N
MB 13.6 N N
RS 10.8 N N
JG 9.5 N 194
DD 7.6 NA NA
AD 7.0 NA NA
HB 6.9 N 197
JM 6.6 NA NA
MG 6.3 NA NA
HG 4.8 N N
Reference range 72-395 30-140
N = normal (within reference range)
NA = results not available.
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Plasma 5-S-CD levels in patients with non-melanoma tumours
The results of the study of non-melanoma tumours are presented
in Fig.3.10. All 38 patients were found to have plasma 5-S-CD
levels which fell within the reference range. The mean 5-S-CD
concentration in each of the groups of patients was not significantly
different from the mean in healthy controls, also shown in Fig.3.10
(independent t-test, p>0-05).
The results of the study of a separate group of patients with
non-melanoma tumours and known metastatic involvement of the liver,
are presented in Fig.3.11. All 10 patients were found to have
plasma 5-S-CD levels which fell within the reference range. The
mean concentration in this group of patients was not significantly
different from the mean in healthy controls (independent t-test,
p> 0-05) .
There was no relationship between LFTs and plasma 5-S-CD in
these patients. Lack of relationship between plasma ALP (which
was markedly elevated in a number of patients) and 5-S-CD indicates
lack of relationship between intrahepatic biliary obstruction and
raised plasma 5-S-CD.
Plasma 5-S-CD levels in patients with abnormal liver function
The results of this study are also presented in Fig.3.11. 3
of the 15 patients had raised plasma 5-S-CD levels, and the results
from these patients are presented in Table 3.6 along with bilirubin,
alanine amino transferase (ALT), ALP and creatinine in these patients.
In 2 of these 3 the 5-S-CD was only marginally elevated; these
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FIGURE 3.10 Plasma 5-S-CD levels in healthy controls and
patients with non-melanoma tumours (individual







































FIGURE 3.11 Plasma 5-S-CD levels in healthy controls and in
patients with non-melanoma liver metastases and
chronic inflammatory liver disease (individual
values plus bar representing mean value)
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Table 3.6 5-S-CD, LFT and creatinine levels in patients with
liver disease
Patient * 5-S-CD Bilirubin ALT ALP Creatinine
(nmol/1) (pmol/1) (U/l) (U/l) (pmol/1)
MW 22.2 148 67 457 57
AW 22.3 27 35 89 60
JR
(30/11) 62.3 64 91 350 72
JR
(28/12) 20.2 62 72 308 89
JR
(16/01) 9.6 53 88 338 93
Reference
range 2-17 10-40 40-100 55-150
origin, respectively. In the third of these patients the plasma
5-S-CD was 3 times the upper limit of the reference range, at 62*3
nmol/1. This patients had alcoholic cirrhosis, with elevated
bilirubin, ALT and ALP. A further 2 samples were obtained from
this patient at intervals of 1 month, and the results are plotted
in Fig. 3.12, showing a return of 5-S-CD levels to normal over this
time whilst the LFTs remained elevated. There was no evidence of
abnormal renal function in any of these 3 patients.
Of the 12 patients with normal 5-S-CD levels, 8 had raised ALP
levels, indicating a lack of relationship between ALP, and therefore
obstructive liver disease, and plasma 5-S-CD, in common with the
findings in patients with metastatic carcinoma involving the liver.
Plasma 5-S-CD levels in patients with chronic renal failure
The results of this study are presented in Fig.3.13. 9 of
the 14 patients were found to have raised 5-S-CD values. The plasma
5-S-CD concentrations and the plasma creatinine concentrations in
these patients are shown in Fig.3.14. There was a significant cor¬
relation between these two variables (r= 0*878). LFTs in these
patients were normal.
Plasma 5-S-CD levels in patients with Parkinson's disease
The results of this study are presented in Fig.3.15. All 6
patients being treated with L-dopa and carbidopa were found to have
raised 5-S-CD levels, whereas the 3 patients being treated with

















































































































































FIGURE 3.13 Plasma 5-S-CD levels in healthy controls and in
patients with chronic renal failure (individual
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FIGURE 3.14 Relationship between plasma 5-S-CD and creatinine
levels in patients with chronic renal failure


















When the studies presented in this thesis were started, Agrup
and coworkers, in Sweden, had already spent several years investig¬
ating urinary 5-S-CD levels in melanoma patients by means of a fluori-
metric method (1979a). This method involved the adsorption of urin¬
ary catechols on to alumina, by the method of Anton and Say.re (1962),
followed by oxidation of 5-S-CD using iodine to produce a fluorophore
with maximum excitation at 325nm and maximum emission at 405nm. It
was found that this method could distinguish 5-S-CD from other cate¬
chols, indoles and analogues of these compounds, and was, therefore,
of high specificity for 5-S-CD. Fluorimetric assays performed in
urine are, however, to some extent notorious because of the presence
of many unknown fluorigens (derived from food or drugs) in urine.
In the case of this particular fluorimetric assay, interference from
certain drugs, such as salicylates, was found to occur (Hansson et al.,
1978).
Prior to the studies presented in the Methods section of this
thesis, fluorimetric assay of urinary 5-S-CD was examined briefly,
using the method of Rorsman et a_l. (1973a). However, the only
fluorimeter available at this time was found to give inconsistent
results and to be insufficiently sensitive to detect the concentra¬
tions of 5-S-CD found in the urine of healthy individuals. In the
absence of suitable equipment, therefore, the study of fluorimetric
measurement of urinary 5-S-CD was not pursued further.
Banda et al. (1977) developed an assay for melanin-related meta¬
bolites, including 5-S-CD, in urine, using ion-exchange separation
and colorimetric detection with the stable free radical diphenylpicryl-
hydrazyl (DPPH). An autoanalyser system, similar to that used by
Banda et al., was constructed. This system incorporated an ion-
exchange column, a mixing coil for reaction with DPPH, a colori¬
meter with flow cell, and a chart recorder. Like the fluorimetric
method, this method was found to be too insensitive to detect the
concentrations of 5-S-CD found in the urine of healthy individuals.
In addition to lack of sensitivity, the analysis of each sample took
up to several hours, as all interfering substances had to be eluted
from the column prior to addition of the next sample. This meant
that only one or two assays could be performed each day, and this
was not considered to be acceptable in the analysis of patient
samples.
Preliminary reports of HPLC assay of 5-S-CD in serum and urine
had appeared in the literature (Hansson et al., 1978, 1979a), and
it seemed that this method was sufficiently sensitive to detect the
concentrations of 5-S-CD found in the serum of healthy individuals,
measuring as low as picogram quantities. HPLC apparatus was obtained
and used, in the first instance, in the study of urinary 5-S-CD levels.
Extraction of urine, prior to HPLC, using the alumina extraction
method of Anton and Sayre (1962), was found to result in very poor
recoveries of 5-S-CD, often as low as 25 percent. As an alternative
to this form of extraction, small columns containing ion-exchange
resin were constructed and samples were put through these columns
prior to assay. Recovery of 5-S-CD from these columns was found
to be in the region of 60 percent. Isoprenaline was being used at
this time as internal standard, due to its structural similarities
to 5-S-CD, however its behaviour on these ion-exchange columns was
not in parallel with that of 5-S-CD and recoveries of isoprenaline
were much lower than those seen for 5-S-CD. It appeared, therefore,
that isoprenaline, although a suitable internal standard as far as
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the HPLC system was concerned, being well separated from 5-S-CD
on the chromatogram, was not compatible with ion-exchange extrac¬
tion of 5-S-CD from urine. Isoprenaline would only be a useful
internal standard in the assay of 5-S-CD when the extraction method
was one which specifically favoured catechol compounds, such as
alumina extraction.
As an alternative to isoprenaline, the possibility of using
radioactively labelled 5-S-CD as internal standard was considered.
This was not available commercially and would therefore have to be
synthesized. Investigation of the availability of labelled sub¬
strates demonstrated that synthesis of labelled 5-S-CD using commer-
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cially available C-cysteine as substrate would result in a product
with insufficient activity to allow detection of the very low mass
required for use as internal standard.
A visit to the laboratories of Rorsman's group in Lund, Sweden,
revealed that they had, in fact, begun to use 5-S-D-cysteinyl-L-dopa,
(5-S-D-CD), a diastereomer of naturally-occuring 5-S-L-cysteinyl-L-
dopa, as internal standard. This was felt to be a particularly
suitable internal standard for use in the assay of 5-S-CD due to the
close similarity between the two compounds. 5-S-CD' is readily
oxidised, and this may result in falsely low values in the measure¬
ment of 5-S-CD in biological samples. Oxidation may occur at a
number of steps, including sample collection, handling, storage or
assay. The similarity between 5-S-CD and its stereoisomer in terms
of both physical and chemical properties means that oxidation of
both isomers is likely to occur in parallel and that loss of 5-S-CD
from a sample due to non-specific oxidation will be mirrored by a
loss of internal standard, and will thus be compensated for in the
calculation of 5-S-CD levels.
5-S-D-CD was synthesized using the tyrosinase reaction des¬
cribed by Ito and Prota (1977). This reaction was found to be
simple to perform, and ion-exchange chromatography of reaction
products resulted in a solution containing approximately 98 per¬
cent pure .5-S-D-CD as determined by HPLC. This solution could be
diluted and used as internal standard. 5-S-D-CD was found to be
well separated from 5-S-CD in a standard solution under varying
chromatographic conditions. However, in urine extracted using
either ion-exchange or alumina, the interference from other meta¬
bolites, oxidised by the electrochemical detector under the same
conditions as the 5-S-CD isomers, was found to be so great as to
prevent adequate detection of both 5-S-CD and 5-S-D-CD in one urine
sample. Under all of the HPLC conditions studied, interference
from other urinary metabolites was a major problem, and a build-up
of contaminants on the HPLC column resulted in these columns having
a very short life. In the face of these problems in the assay of
urinary 5-S-CD using HPLC, studies were begun to examine the assay
of 5—S-CD in plasma or serum.
There are a number of advantages in the use of an assay involv¬
ing plasma or serum over an assay involving the collection of 24
hour urine samples. Although the collection of urine samples is
relatively simple from a patient in a hospital ward, the organis¬
ation of outpatients and study volunteers is not so easy. It is
inconvenient to carry a bottle around for a whole day and difficult
to remember to collect every specimen during that time. For this
reason, 24 hour samples may be incomplete, resulting in inaccurate
estimation of the substance under study. As far as the subject of
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the study is concerned, therefore, the collection of a small blood
sample is usually preferable to a 24 hour urine collection. From
the point of view of analysis, a few millilitres of blood is more
f
manageable than litres of urine. Measurement of 5-S-CD in a single
blood sample does have disadvantages, however, when compared to its
measurement in a 24 hour urine specimen, the most important being
its ability to reflect only the state of 5-S-CD production and ex¬
cretion at a single point in time rather than over a 24 hour period,
and this should be borne in mind in interpretation of results.
Study of both serum and plasma suggested that there was no sig¬
nificant difference in 5-S-CD levels found in the two media, and it
was decided that plasma was more convenient to use routinely.
Modification of the alumina extraction procedure which had been used
previously in the studies of urine, and use of 5-S-D-CD as internal
standard, resulted in a procedure which could be used to give an
extract of plasma which could then be simply analysed by HPLC. The
HPLC system was modified from that of Hansson et al. (1979a) to give
good separation of 5-S-CD from both interfering metabolites in plasma,
and the internal standard. The alumina extraction procedure was
such that a substantial number of samples could be extracted in one
batch, ready for HPLC analysis. Extraction of both cysteinyldopa
isomers from the plasma was found to be approximately 50 percent,
which, although quite poor gave sufficient levels in the resulting
extract to allow adequate detection and measurement. The similar
extraction efficiencies for the two isomers demonstrated the suit¬
ability of 5-S-D-CD as internal standard in this procedure. The
HPLC procedure was found to be reproducible, as demonstrated by the
intra- and inter-assay coefficients of variation, both less than 5
percent. Quality control samples were analysed with each batch of
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patient samples to check reproducibility and to allow for any bad
set of assays to be disregarded.
The major problem with the assay was found to be in the day to
day variation in performance of the electrochemical detector. Thi
could sometimes be related to some extraneous interfering factor,
but was often quite inexplicable. The main factors which seemed
to affect the detector were draughts, and power surges caused by
the switching on and off of other equipment in the laboratory.
These factors were often difficult to control and made the assay
difficult to perform. Often baseline noise was so great as to
prevent reasonable determination of 5-S-CD levels, and although
this could on some occasions be overcome by some simple procedure
such as polishing the detector electrode or making up fresh mobile
phase, on some occasions it was not possible to overcome these
problems and the assay had to be postponed.
Other forms of detection linked to HPLC have been used in the
measurement of catecholamines. Fluorimetric monitoring following
post-column derivatisation has been used in the measurement of
adrenaline, noradrenaline and dopamine (Honda et al., 1983).
However, most of the fluorimetric methods examined have been found
to be tedious to perform and somewhat subject to interference from
dietary factors and drugs.
UV detection has also been used in the measurement of catechol
amines but does not appear to be as sensitive a method as electro¬
chemical detection (Mell and Gustafson, 1977).
The temperamental nature of electrochemical detectors when use
at the high sensitivities required for the detection of 5-S-CD in
plasma limits the usefulness of this method in routine analysis,
particularly in situations where it may have a number of different
operators, none of whom can afford to spend a lot of time sorting
out difficulties in the day to day running of the system. However,
in the situation presented here, where the method was being used as
a research tool, and where there was only one operator who was able
to spend time sorting out problems, this method was found to be both
sensitive,* detecting low picogram quantities of 5-S-CD, and specific
for detection of this compound.
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PLASMA 5-S-CD STUDIES
Having developed a method for the detection and measurement
of 5-S-CD in plasma, and determined its performance and some of the
problems likely to occur in its use, the next step was to use the
method to obtain some background information about plasma 5-S-CD.
Plasma 5-S-CD in healthy volunteers
Measurement of plasma 5-S-CD levels in healthy volunteers over
a period of time led to the acceptance of 20 nmol/1 as the upper
limit of normal 5-S-CD levels.
The demonstration by Rorsman et al. (1976) and by Nixon (1978)
of the sensitivity of urinary 5-S-CD levels to exposure of the skin
to sunlight prompted the study of plasma 5-S-CD levels in the climate
of S.E. Scotland. The study extended over a 12 month period in an
attempt to determine whether plasma 5-S-CD levels varied with season,
as shown with urinary 5-S-CD in other climates, particularly that
of S. Sweden (Rorsman et al., 1976).
Measurement of 5-S-CD levels over a 12 hour period demonstrated
minimal variation throughout the day, making it unnecessary to obtain
samples at a particular time of day (this is important when using
a single blood sample in place of a 24-hour urine sample).
The time of month at which plasma samples were taken for the
seasonal study depended solely on when subjects were available, and
samples from different volunteers were, therefore, obtained at
different times of the month. A significant increase in plasma
5-S-CD levels was observed during the summer months, with a mean of
6*3 nmol/1 in December rising to a mean of 11-9 nmol/1 in June.
The largest increase in 5-S-CD level seen in an individual subject
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was just less than 3-fold.
The increases in urinary 5-S-CD concentrations observed by
Rorsman et- al. (1976) were more marked than the increases in plasma
5-S-CD seen here, with a mean of 60 pg/24h in winter rising to a
mean of 191 pg/24h in summer. In some subjects, 4-5 fold increases
in 5-S-CD excretion were observed.
In common with the Swedish study it was seen here that the
scatter of 5-S-CD values was greatest during the summer months,
although the subjects who had the highest values in winter tended
to also have the highest values in the summer.
A number of the subjects who participated in the Edinburgh
study travelled abroad for holidays during the summer months.
Plasma 5-S-CD was measured before the holiday and immediately on
return from holiday. Plasma 5-S-CD levels in these subjects on
return from abroad were no higher, in general, than those seen in
subjects who had not travelled abroad on holiday.'
Nixon (1978) demonstrated that increases in urinary 5-S-CD
levels as high as 10-fold may occur several days after initial ex¬
posure to sunlight, but that this level will return to baseline
within a matter of weeks after irradiation. It may be that although
increases in plasma 5-S-CD levels occurred in the subjects in the
seasonal study who travelled abroad and became tanned, by the time
these subjects returned home and had a post-holiday 5-S-CD measure¬
ment, the levels had already returned to baseline, or were decreasing
towards baseline levels. This explanation would be consistent with
later findings in patients with psoriasis undergoing treatment with
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UVB (which is similar to the UVR that volunteers would have received
on holiday), in whom the increase in plasma 5-S-CD levels seen on
exposure to UVB occurred early, reaching a peak 2 to 10 days after
the start of treatment, and thereafter returned towards pre-treatment
levels (Fig.3.5). The results from these subjects were included
in the study although the subjects had not been exposed solely to
the climate of Edinburgh. It seemed, however, that the major fac¬
tor influencing 5-S-CD levels in the subjects included in this study
was the natural sunlight in Edinburgh, and this was sufficient to
produce a significant increase in 5-S-CD levels during the summer
months, in all subjects under study. Although significantly in¬
creased, the levels in these subjects did not exceed the arbitrarily
chosen upper limit of normal values of 20 nmol/1. It seemed, there¬
fore, that in choosing this upper limit of normal values, even during
the summer months 5-S-CD levels would not be expected to rise above
the limit. It must not be forgotten, however, that this chosen
level .is an arbitrary one and that levels exceeding it should still
be interpreted with caution, particularly during the summer months.
Plasma 5-S-CD and UVR
The study of psoriasis patients undergoing treatment with UVB
or PUVA demonstrated the marked effect that exposure to large amounts
of UVR can have on plasma 5-S-CD levels.
The reaction to PUVA therapy varied considerably from one patient
to another. In some patients the change in 5-S-CD levels was seen
as a rapid increase, reaching a peak several days after the start
of treatment, followed by a return to pre-treatment levels over the
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next few days. However, in other patients this rise in 5-S-CD
was followed not by a return to baseline but by continually fluc¬
tuating levels throughout the remainder of the course of treatment.
The initial results of this study seemed to point to a relationship
between the skin type of the patient and the changes in plasma
5-S-CD levels seen in response to PUVA therapy. Patients with
skin types III or IV seemed to exhibit the first pattern of 5-S-CD
change, with a rise in levels followed by a return to baseline.
Patients with type I or II skin, however, seemed to have plasma
5-S-CD levels which fluctuated throughout treatment. The apparent
relationship between skin type and plasma 5-S-CD could be explained
by considering the response of these groups of patients to UVR in
terms of tanning and erythema. In patients with skin types III and
IV, initial exposure to UVR could stimulate the melanocytes to produce
the increased 5-S-CD levels seen initially, but as melanogenesis it¬
self resulted in increased pigmentation of the skin, with consequent
absorbance and scattering of UVR, the UVR would be prevented from
influencing the melanocytes to the same extent and 5-S-CD production
would, with decreased stimulation, return to normal. Patients with
skin types I and II, however, develop little or no skin pigmentation
in response to UVR, so no barrier is produced to the UVR, and sub¬
sequent doses are able to stimulate production of 5-S-CD by the mel¬
anocytes in the same way as the initial dose, resulting in fluctuating
plasma 5-S-CD levels throughout the course of treatment in these
patients.
These findings, and the hypothesis formulated on the basis of
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them, were not, however, supported by study of further patients, in
whom the response to PUVA and its relationship with skin type did
not appear to be clear cut.
The response of patients to UVB therapy was less marked than
the response to PUVA therapy. Although the doses of UVB received
by these patients were an order of magnitude smaller than the doses
of UV received in the PUVA study, it is not possible to compare
directly the two forms of therapy and attribute the smaller responses
in UVB patients simply to the smaller doses of UVR received. UVA
and UVB have been shown to cause distinct and specific cellular and
subcellular changes in the epidermal melanin unit (Pathak et al.,
1976). UVA has been shown to cause less erythema and to be more
effective in induction of melanogenesis than UVB. Also, in PUVA
therapy, UVA is given in conjunction with' 8-methoxypsoralen, which
is able to enhance the effects of UVA on melanogenesis.
The initial rise in 5-S-CD, in both groups of patients, occurred
before any tanning was present, and it seemed, therefore, that the
increased 5-S-CD was not related to the tanning induced by the UVR
exposure. The rise in 5-S-CD occurred, however, at a time when
erythema was often present, particularly in patients with skin types
I and II. This may indicate some association between increased
5-S-CD levels and skin inflammation or damage, as suggested in a
number of studies by other workers (Hansson et a_l. , 1981; Tegner,
1983; Tegner et al., 1983a, b). Alternatively, the initial rise
in 5-S-CD levels may have occurred as a result of stimulation of
melanogenesis by UVR, with intermediates such as 5-S-CD being released
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into the bloodstream before any increase in pigmentation had occurred.
The possible association between plasma 5-S-CD and skin damage
suggested by Tegner (1983) is not supported by this study in that
the patients with the most marked rises in plasma 5-S-CD in response
to UVR were not necessarily those who developed the most marked
erythema. * However, to investigate further the possibility that
cutaneous cell damage may bring about increased 5-S-CD levels in
the plasma, 6 psoriasis patients receiving topical dithranol were -
studied. This treatment often induces an irritant erythema which,
although limited to the areas treated, is similar to that induced
by exposure to UVR. Although slight rises in plasma 5-S-CD levels
were observed in 3 of these 6 patients, no significant relationship
between appearance of dithranol-induced erythema and rises in plasma
5-S-CD levels could be demonstrated.
It seems likely that the changes in plasma 5-S-CD concentration
which occur in response to UVR are not due to any single factor, but
may be due to a combination of stimulation of melanogenesis and cut¬
aneous cell damage, involving keratinocytes and melanocytes, both
of which can occur as a result of exposure to UVR.
Pathak et al. (1976) have examined the effects of UVR on skin-
pigmentation at the microscopic level. Light and electron micro¬
scopic observations on delayed tanning reactions, induced by single
or multiple exposures to UVA, UVB or UVA plus 8-methoxypsoralen
(PUVA), were examined in vivo in human skin, biopsied following
exposure to UVR. A single exposure to any of these treatments did
not cause an increase in the number of functional melanocytes but
132.
caused an increase in the synthesis and melanisation of melanosomes.
Multiple exposures caused a marked increase in number of melanocytes,
synthesis of melanosomes and degree of melanisation. Increased
tyrosinase activity following UVR was demonstrated by incubation of
the skin specimens with dopa and observation of an increase in melanin
pigmentation. A biproduct of this increased tyrosinase activity
in melanocytes is likely to be 5-S-CD, and increased excretion of
this intermediate may well be observed before increased skin pig¬
mentation itself is apparent.
As far as skin damage is concerned, part of the mechanism of
cell damage by UVR appears to involve lysosome membrane damage and
release of the lysosomal contents into the cell cytoplasm (Daniels
and Johnson, 1974). The possibility that melanosomes situated in
the keratinocytes are also damaged by exposure of the skin to UVR
seems likely, as demonstrated by the presence of melanin in the
cytoplasm of so-called 'sunburn cells' (Daniels and Johnson, 1974)•
Whether melanin precursors normally present in melanosomes may,
therefore, be released by the damaging effects of UVR, is not clear
from these studies.
Another possible explanation for some of these findings lies
in the known production of reactive free-radicals in the skin in
response to UVR (Norins, 1962; Pathak and Stratton, 1968), and the
possibility that these molecules may have a part to play in 5-S-CD
production is discussed on page 135.
Plasma 5-S-CD in relation to skin and hair colour
Comparison of plasma 5-S-CD levels in individuals with red hair,
with levels in individuals with blonde or brown hair, demonstrated
that there was no significant difference between the results from
the 2 groups. The predominance of the red/ye.llow phaeomelanins in
the hair of red-headed subjects suggested that these subjects may
be producing larger amounts of phaeomelanin precursors, such as
5-S-CD, than subjects with other hair colours. Red hair has,
however, been shown to contain no 5-S-CD that can be extracted
with perchloric acid, although trichochromes B and C have been
isolated from red hair (Rorsman et al. , 1979). These results are
similar to the findings of Agrup et al. (1975b) who demonstrated
that there was no statistically significant difference in urinary
excretion of 5-S-CD between subjects with red, blonde or dark hair
This was further supported by findings of comparable urinary 5-S-CD
levels in healthy Japanese subjects (Morishima and Hanawa, 1981).
The 5-S-CD concentrations seen in.the plasma of black-skinned
subjects were similar to those seen in white-skinned subjects.
This finding is predictable since there is no disparity in the
melanocyte numbers between blacks and whites, the pigmentary diff¬
erences being mainly due to differences in number, size, distribution
and breakdown of melanosomes (Billingham, 1949; Szabo £t ad., 1969).
Excretion of 5—S-CD in the urine of dark-skinned subjects was noted
by Agrup et al. (1979b), and in this case was found to be lower than
excretion in white-skinned individuals.
It appears from this study of skin and hair colour that differ¬
ences in these factors, as genetically determined, do not result in
differences in plasma 5-S-CD levels.
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Plasma 5-S-CD in oculocutaneous albinism
Any study of pigmentation would not be complete without including
a group of individuals in whom melanin pigmentation is either greatly
reduced or completely absent, such as individuals with oculocutaneous
albinism. Study of 20 such patients, 10 with tyrosinase-negative
(ty-neg) apd 10 with tyrosinase-positive (ty-pos) OCA, produced some
unexpected findings. Ty-pos albinos were found to have 5-S-CD
values which did not significantly differ from the values seen in
normally pigmented individuals. The defect in ty-pos OCA is unknown,
and tyrosinase activity in the hairbulbs of these individuals is
apparently unaffected (King and Witkop, 1976). Normal 5-S-CD levels
in these individuals can, therefore, be easily explained. Normal
5—S-CD values in ty-neg albinos are, however, more remarkable, in
light of the lack of active tyrosinase in these individuals (King
and Witkop, 1976). Aquaron et al. (1981) have demonstrated normal
urinary excretion of 5-S-CD in ty-neg albinos in the sunny climate
of Cameroon, in keeping with these results.
Although ty-neg albinos do not have the enzyme tyrosinase in
their melanocytes, they do have the enzyme tyrosine hydroxylase in
sympathetic nerve endings and adrenals. This enzyme catalyses the
conversion of tyrosine to dopa, and is necessary for the production
of catecholamines. Ty-neg albinos are, therefore, able to produce
dopa. In order for the production of 5-S-CD to proceed, this dopa
must be oxidised to the reactive dopaquinone. Since the addition
of cysteine or other sulphydryl compounds to o-quinones is a rapid
spontaneous reaction, any oxidising system with the capacity to
convert catechols to o-quinones would be able to cause conjugation
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of catechols with sulphydryl compounds. Several such systems are
known, and their ability to bring about cysteinyldopa formation has
been examined (Ito and Fujita, 1981a, b, 1982). Ito and Fujita
have examined a number of systems, including peroxidase, superoxide
and hydroxy1 radicals (0^ and OH'), and iron-EDTA complex. Perox¬
idase was shown to be capable of bringing about the formation of
cysteinyldopas in vitro under the conditions studied. This enzyme
is detectable in a variety of cells, and has even been implicated
in mammalian melanogenesis (Okun et al., 1973). However, there is
much evidence to suggest that the enzyme in question in this situa¬
tion is tyrosinase rather than peroxidase (Hearing and Ekel, 1975;
Smith and Swan, 1976).
A superoxide radical (0^) is generated in many biological proc¬
esses, and acts as an oxidant on a number of compounds, including
catechols and sulphydryl compounds. Ito and Fujita studied the
superoxide radical generated by the action of xanthine oxidase on
hypoxanthine, to see whether this radical was capable of mediating
the formation of cysteinyldopas from dopa and cysteine. They found
that the 0^ radical generated in this way reacted with dopa to prod¬
uce cysteinyldopas at a much faster rate than its reaction with
cysteine to produce cystine.
The hydroxyl radical (OH*) generated from the iron-EDTA complex
(Fe^+-EDTA) and hydrogen peroxide was also found to be capable
of bringing about conjugation of dopa with cysteine.
These results demonstrated that cysteinyldopa formation can be
mediated in vitro by peroxidase, superoxide and hydroxyl radicals,
and by oxygen in the presence of iron chelate (perhaps through prod¬
uction of and OH* radicals). They therefore suggest that
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production of cysteinyldopas in vivo may not necessarily be dependent
on tyrosinase activity, as these other oxidising systems are known
to occur in the cells of the body and may bring about these reactions
in vivo.
Non-enzymic production of 5-S-CD has been demonstrated in non-
melanin-producing tissues of the rat, mouse and cow, and in hair
of ty-neg mice and white mice, completely lacking in follicular
melanocytes (Fehling et al. , 1981; Ito et al. , 1983). Urinary
excretion of 5-S-CD was found to be no different between black and
albino mice.
It seems likely that the presence of protein-bound 5-S-CD in
certain tissues of mice and rats, including albino mice, is due to
its synthesis from protein-bound dopa, perhaps by one of the non¬
specific oxidation systems examined by Ito and Fujita (1981b).
Protein-bound dopa is found in high concentrations in these tissues
relative to the concentrations of free dopa, and is presumably
produced by the action of tyrosine hydroxylase on tyrosine. Turn¬
over of the 5-S-CD-containing proteins would account for excretion
of 5-S-CD in the urine. Although little is known of the situation
occurring in humans, it may well be that a similar situation exists
and that the 5-S-CD detectable in the plasma of ty-neg albinos is
being produced in a similar manner to that suggested for albino mice.
The likely existence of some non-tyrosinase mechanism for 5-S-CD
production in ty-neg albinos brings into question the site and mech¬
anism of production of 5-S-CD in normally pigmented individuals.
It is possible that some 5-S-CD production in these individuals,
rather than being mediated by tyrosinase in the melanocytes, occurs
in the same way as in albino subjects.
The presence of 5-S-CD in the urine of ty-neg albino negro
subjects from Cameroon has been noted, as previously mentioned,
and levels in these subjects found to be greater than the levels
in normally pigmented negro subjects (Aquaron et al. , 1981). The
explanatioh offered for these findings was the existence of a block
in the melanin pathway at some point distal to tyrosinase, perhaps
by melatonin or dopachrome conversion factor, creating a build-up
of pathway intermediates. The results of the study of ty-neg
albino subjects presented here are.dissimilar, in that levels of
5-S-CD in their plasma are no different from those seen in normally
pigmented controls. Although plasma 5-S-CD has been shown to re¬
flect melanocyte activity under certain conditions such as UVR ex¬
posure, it may be that normal baseline 5-S-CD levels do not exclus¬
ively reflect melanocyte activity, being perhaps due in part to non-
tyrosinase oxidation of dopa at other sites in the body, and that
it is only under abnormal or stimulated conditions that measurement
of plasma 5-S-CD acts as an index of melanogenesis.
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Plasma 5-S-CD in malignant melanoma
Malignant melanoma (MM), although the most malignant of skin
tumours, if diagnosed and treated early, is curable. Obviously,
therefore, the most important factor in the effective treatment of
this tumour, in common with many other tumours, is its early recog¬
nition and removal (Pondes et al. , 1981).
Study of patients with stage I primary melanoma demonstrated
that plasma 5-S-CD levels were not significantly different from levels
in normal healthy subjects or in subjects with a range of other prim¬
ary tumours. Measurement of plasma .5-S-CD in these patients is,
therefore, of no value in diagnosis of the primary tumour, and
definitive identification depends upon surgical excision and histo¬
logical examination of the excised tissue.
Agrup et al. (1977a) demonstrated normal urinary excretion of
5-S-CD in patients with primary melanoma. They also demonstrated
that a proportion of patients with metastatic melanoma had raised
urinary 5-S-CD concentrations, suggesting that measurement of urinary
5-S-CD may be of value in the diagnosis of secondary melanoma.
The value of plasma 5-S-CD measurements in patients being followed
up after removal of primary melanoma or locally involved nodes was
examined in a study of all patients attending the Dermatology melan¬
oma follow-up clinic over a period of 1 year, all of whom were thought
to be disease-free following surgery. Of the 88 patients in this
group, 9 developed metastases either during the study period or in
the 8 months following completion of the study. In 4 of these 9
patients raised plasma 5-S-CD levels were detected prior to the !
development of any other clinical or biochemical signs of metastatic
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disease. The 2 patients whose 5-S-CD levels are presented in
Fig.3.8 are included in this group. In the first of these patients
(TI) this raised plasma 5-S-CD level was first observed when the
patient was still apparently well and showing no signs of recurrence
of the tumour. Two months after this first raised 5-S-CD level
the patient began to develop clinical and other biochemical signs
indicating the presence of secondary tumour, in this case the devel¬
opment of a right-sided pleural effusion and abnormal liver function
tests, indicative of pulmonary and hepatic metastases. The patient
died within a month of clinical diagnosis of metastatic disease.
The second patient (HI) whose plasma 5-S-CD levels are presented
in Fig.3.8 was found to have a slightly raised 5-S-CD level on atten¬
dance at the Dermatology follow-up clinic in March '83. On 3 sub¬
sequent visits to the clinic her plasma 5-S-CD was found to be within
the reference range. A second raised level, this time very marked¬
ly raised at l.lpmol/1, was seen 8 months after the first raised
level, in November. Shortly after detection of this very high
5-S-CD the patient began to feel generally unwell, with nausea,
vomiting and abdominal pain. Further investigation showed pulmonary
metastases on chest X-ray, and hepatic metastases were demonstrated
by liver ultrasound and abnormal liver function tests. This patient
died within a few weeks of clinical diagnosis of metastatic disease.
Both of these patients died approximately 2 months after the
finding of a raised plasma 5-S-CD level. In the case of HI this
was actually 10 months after the detection of a slightly raised
5-S-CD level which was not pursued, due to the finding of normal
5-S-CD levels on 3 subsequent occasions. Whether this particular
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patient should have been further investigated on the basis of one
slightly raised 5-S-CD level is difficult to say as it is not clear
why a patient should have a raised level on one occasion and a nor¬
mal level on the following occasion. If plasma 5-S-CD is related
to the presence of clinically undetectable metastases, as seems
likely, it may be that it reflects some growth spurt of the second¬
ary tumour with production of melanin precursors and melanin.
The 2 remaining patients who were found to have raised 5-S-CD
levels prior to the development of other signs of secondary melanoma,
had these raised levels 2 and 9 months prior to clinical diagnosis
of metastases, respectively. The raised 5-S-CD levels in both of
these patients were only marginally elevated above the 20nmol/l
upper limit, at 25-7 and 24-6 nmol/1, respectively. These raised
levels were measured towards the end of the year in which these
patients were studied, and so the progression of disease in these
patients could not be followed. It may well have been the case
that as the metastatic disease progressed and other signs became
apparent, the plasma 5-S-CD levels became more markedly elevated.
The further 3 patients who developed metastases in the 8 months
following the study, who did not at any time during the study have
elevated 5-S-CD levels, may also have had raised levels prior to the
clinical detection of metastases which occurred at a time when plasma
5-S-CD levels were no longer being measured routinely and were,
therefore, not detected.
There were a further 2 patients who developed metastases within
the year of study who did not have raised plasma 5-S-CD levels even
after metastases were clearly present. One of these patients had
a large abdominal secondary tumour removed which was barely pigmented
and was found, on histological examination to contain little or no
melanin pigmentation. A normal plasma 5-S-CD in this patient could,
therefore, be simply explained in terms of lack of melanin production
by the very undifferentiated tumour cells. Tumour tissue from the
second patient who came into this category was not available for
examination, so its pigmentary status remains unknown, although it
would seem reasonable to predict that this tumour would also have
been found to be amelanotic or weakly pigmented. Obviously it is
not possible to formulate a hypothesis about the relationship between
the pigmentary status of secondary melanoma and plasma 5-S-CD levels
on the basis of the findings in one individual patient. However,
Agrup et al_. (1979a) found that normal urinary excretion of 5-S-CD
in the presence of metastatic melanoma (which occurred in 10% of the
patients whom they studied) did not have a single explanation. Some
metastases in these patients were amelanotic or weakly pigmented,
some were solitary and/or small, but normal values were also found
in some patients with numerous pigmented metastases.
It is impossible to predict whether a patient will develop
metastases producing massive amounts of melanin, or completely non-
pigmented metastases on the basis of the nature of the primary tumour,
as there appears to be no relationship between the two. Patients
may have a deeply pigmented primary tumour which metastasises to
produce an amelanotic secondary tumour. The only way to determine
the pigmentary status of a secondary tumour is, therefore, to remove
the tissue and examine it, both grossly and microscopically, for the
presence of melanin. This procedure appeared to be performed rarely
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in stage III melanoma patients as the nature of metastases is usually
obvious clinically. It was, therefore, very difficult to obtain
information on the pigmentation of the secondary tumour tissue.
Study of 26 patients with known stage III metastatic melanoma
at the time of 5-S-CD measurement produced results in keeping with
those from* melanoma follow-up patients developing stage III melanoma
during the course of study. Approximately 60 percent of the 26
patients studied were found to have raised plasma 5-S-CD levels,
and in those from whom more than one sample was obtained for 5-S-CD
estimation, all subsequent samples also had elevated 5-S-CD levels
The remaining 40 percent of patients had normal 5-S-CD levels on each
occasion in spite of the presence of metastatic tumour. A number
of the patients in this group were known to have metastatic deposits
in the liver, and examination of liver function in the 26 patients
showed that of the 15 with raised plasma 5-S-CD levels, 11 also had
abnormal liver funtion tests (LFTs), with either lactate dehydrogenase
(LDH) or alkaline phosphatase (ALP), or both, being elevated. This
compared with 2 out of 6 patients with normal 5-S-CD levels having
abnormal LFTs. Results of LFTs were not available for the remaining
5 patients with normal 5-S-CD levels. These results could be inter¬
preted as indicating some association between liver metastases and
raised plasma 5-S-CD levels although there were, of course, 4 patients
in whom an elevated 5-S-CD was not associated with abnormal LFTs. A
possible relationship between liver metastases and plasma 5-S-CD
levels suggests that the raised 5-S-CD levels may be due not simply
to the presence of melanoma cells which are producing abnormally high
levels of 5-S-CD, but that impairment of liver function, by the pres¬
ence of metastatic deposits, may also be a contributory factor.
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This in turn suggests a role for the liver in the normal metabolism
of 5-S-CD, which is discussed in the following section. The poss¬
ibility also exists that the finding of high 5-S-CD levels in these
patients with abnormal liver function simply reflects high tumour
bulk in these patients and an increased likelihood of spread to the
liver.
These studies in melanoma patients demonstrated that whereas
plasma 5-S-CD levels were not abnormal in patients with stage I
primary melanoma, approximately 60 percent of patients with second¬
ary melanoma had raised 5-S-CD levels. In a number of cases, 5-S-CD
levels were shown to be elevated prior to clinical or other biochem¬
ical signs of metastatic disease. In 4 patients (1 follow-up patient
and 3 with known stage III disease at time of study) it was possible
to relate normal 5-S-CD levels to the amelanotic nature of the sec¬
ondary tumour tissue, although in the majority of cases tumour tissue
was not available for examination of its pigmentary status.
The results of the study of patients being followed up after
surgery for stage I or stage II melanoma indicate that, in some cases,
measurement of plasma 5-S-CD on attendance at the follow-up clinic
can be a useful addition to clinical examination of the patient, and
can occasionally indicate the presence of stage III melanoma prior
to any clinical signs of progressing disease. The small number of
patients in this group who developed stage III melanoma during the
study, and the even smaller number in whom an increased 5-S-CD level
was the first sign of spread of disease, suggest that the measurement
of plasma 5-S-CD levels in all follow-up patients on each attendance
at the clinic is probably not a worthwhile procedure. However, it
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may be that plasma 5-S-CD estimation is a useful follow-up procedure
in patients who had either a thick stage I primary tumour, or stage
II melanoma, prior to surgery, as indicated by the proportion of
patients who developed stage III melanoma and who had previously
either a relatively thick stage I tumour (5 of the 7 in whom Breslow
measurements were available had tumours thicker than 2mm), or stage
II melanoma (1 of the remaining 2 patients had stage II melanoma
prior to surgery).
Nevertheless liver function in a high proportion of patients
with secondary melanoma and raised 5-S-CD levels, was impaired,
suggesting a possible relationship between liver function and plasma
5-S-CD levels, and prompting further investigation of liver function
and its relationship to 5-S-CD.
Plasma 5-S-CD and liver function
A group of patients with non-melanoma malignant tumours but
without known liver involvement were studied. These tumours in¬
cluded breast, lung, ovary and stomach cancers, and lymphoma, and
in all 38 patients 5-S-CD levels were found to be normal.
A further 10 patients with miscellaneous malignant disease were
studied, all of whom had known metastatic involvement of the liver
and deranged liver function. Although LFTs in these patients were
abnormal, 5-S-CD levels in all patients were normal. This study
does not support the theory that raised plasma 5-S-CD levels may be
simply related to the presence of metastatic tumour in the livers
of melanoma patients, despite the fact that in many cases their
liver function was grossly abnormal.
The liver is a common site for metastatic spread of melanoma,
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and it is possible that in patients with widespread secondary disease
and multiple metastases, who have raised plasma 5-S-CD levels as a
consequence of the high tumour load present, the finding of meta¬
static tumour in the liver is highly probable, resulting in abnormal
liver function which is not directly related to the level of 5-S-CD
in the plasma.
Abnormal ALP levels in 2 of the 6 patients with stage III mel¬
anoma and normal plasma 5-S-CD levels may indicate the presence of
widespread amelanotic or weakly pigmented tumour in these patients.
To examine further the handling of 5-S-CD by the liver and the
effect of deranged liver function on plasma 5-S-CD levels, a group
of patients with liver disease, in the form of chronic hepatitis or
cirrhosis, was examined. All of these patients had markedly ab¬
normal LFTs. Measurement of plasma 5-S-CD levels in these patients
demonstrated that all but 3 of the 14 patients in this study had
normal 5-S-CD levels, and 2 of the 3 elevated levels were only very
slightly raised above the limit of 20 nmol/1. The third abnormal
5-S-CD was greater than 3 times this figure at 62-5 nmol/1. The
patient in whom this level was seen had alcoholic cirrhosis and
highly abnormal LFTs at the time of this 5-S-CD measurement. He
was seen at monthly intervals over the following 2 months and had
5-S-CD and LFT measurements performed on each occasion. His bili¬
rubin and ALP levels remained considerably elevated over this period,
but his 5-S-CD was seen to return to normal. The patient had no
history of malignant melanoma, was apparently on no medication which
would account for this raised 5-S-CD, and had not recently been ex¬
posed to large amounts of UVR. The explanation for the raised
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5-S-CD in this man is not clear. However, the finding of elevated
plasma 5-S-CD levels in patients with abnormal liver function appeared
to be very uncommon, and it seemed that in general, abnormal liver
function does not cause elevated plasma 5-S-CD levels, and that the
apparent relationship between these 2 factors in stage III melanoma
is simply due to high tumour load in these patients.
The role of the liver in 5-S-CD metabolism has been investigated
(Agrup et al., 1977b). Catechol-O-methylation is known to be impor¬
tant in the metabolism of dopa, and large amounts of the product of
this reaction, 3-methoxytyrosine, have been detected in the urine
of patients with malignant melanoma. Large amounts of dopa are
also decarboxylated to form dopamine, which is also detectable in
the urine. These two reactions are shown in Fig.4.1. Incubation
of 5-S-CD with rat liver extract containing large amounts of catechol-
O-methyl transferase and S-adenosylmethionine, has been shown to
result in the production of a methyl derivative of 5-S-CD, identified
by gas chromatography-mass spectrometry (GC-MS). This same methyl
derivative was also detected in large amounts in the urine of 2 melan¬
oma patients. Incubation of 5-S-CD with guinea-pig kidney extract
containing dopa decarboxylase did not result in the formation of
5-S-cysteinyldopamine detectable by GC-MS, nor could any of this com¬
pound be demonstrated in the urine of the 2 melanoma patients.
It appears from these studies that metabolism of 5-S-CD is
largely by methylation, with decarboxylation playing a minor role,
if involved at all. Although large amounts of the methyl deriva¬
tive of 5-S-CD were found in the urine of melanoma patients, it is












FIGURE 4.1 Metabolism of dopa in the liver and kidney
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the unmetabolised 5-S-CD. Whether O-methylation plays a major
role in the handling of 5-S-CD by the body under normal conditions
is not clear, and whether the relative amounts of 5-S-CD and its
methyl derivative excreted under conditions of abnormal liver func¬
tion are different to those found in normal liver function is
unknown.
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Plasma 5-S-CD and renal function
5-S-CD is excreted in relatively large amounts in urine, as
compared to the low levels present in the plasma of healthy indiv¬
iduals, which are undetectable by fluorimetric measurement (Agrup
et al., 1975b).
Calculation of renal clearance of 5-S-CD in melanoma patients
with high plasma 5-S-CD levels has suggested that approximately
50 percent of the 5-S-CD filtered in the glomeruli is excreted in
the urine, unlike most amino acids which are more effectively re¬
absorbed by the kidney tubules (Agrup et al., 1975a). Whether a
similar situation occurs in healthy individuals with much lower
plasma levels of 5-S-CD is unknown. The kidney, however, obviously
plays a major role in the handling of 5-S-CD by the body, excreting
both 5-S-CD and its 0-methyl derivative in relatively large amounts.
Renal function, and its effect on plasma 5-S-CD levels was in¬
vestigated in 14 patients with miscellaneous forms of chronic renal
failure. Results from these patients demonstrated a strong correl¬
ation between glomerular function, as estimated by plasma creatinine
levels, and plasma 5-S-CD concentrations. The plasma 5-S-CD levels
seen in some of these patients were more than twice the upper limit
of 20nmol/l, and only 5 of the patients had levels which fell within
the reference range. Clearly, impairment of glomerular function is
able to have a significant effect on plasma 5-S-CD levels. This
may be directly due to decreased glomerular filtration in these
patients, as suggested by the relationship between plasma 5-S-CD and
creatinine levels. However, it may indicate that the kidney has
some role to play in metabolism of 5-S-CD•, since large amounts of
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catechol-O-methyl transferase are known to be present in the kidney.
Hansson £t al. (1979b) have studied serum levels of dopa and
a number of dopa metabolites in uraemia and in patients on renal
dialysis. Serum concentrations of 5-S-CD, but not dopa, were found
to be increased in renal insufficiency, possibly explained by the
fact that dopa, unlike 5-S-CD, is decarboxylated. Hansson et al.
also found that plasma clearance of 5-S-CD was more impaired than
creatinine clearance in patients with chronic renal failure. They
concluded that the changes in serum concentrations of 5-S-CD and
related compounds in renal failure were probably due directly to the
impaired renal function, but that indirect mechanisms may also be of
importance.
Impaired renal function was considered as a possible contributory
factor in earlier studies of melanoma patients with highly elevated
plasma 5-S-CD levels. Renal function, however, unlike liver func¬
tion, was not commonly impaired in our patients. However, the fact
that impairment of renal function can cause such marked abnormalities
in plasma 5-S-CD levels suggests that this is a factor which should
be considered in melanoma patients with elevated 5-S-CD levels, as
it may produce misleading results in patients suspected of having
metastatic disease.
Plasma 5-S-CD in Parkinson's disease
The finding of a highly elevated plasma 5-S-CD level (172 nmol/1)
in a melanoma follow-up patient led to the assumption that this pat¬
ient had developed metastatic melanoma. However, this patient also
had Parkinson's disease, which was being treated with the drug Sinemet,
a combination of L-dopa and carbidopa.
Parkinson's disease, a neurological condition involving mus¬
cular rigidity, hypokinesis and tremor, has long been known to be
related to abnormal function in the basal ganglia. The basal
ganglia receive a strong dopaminergic innervation, and the disease
is associated with a reduced amount of dopamine in the brain. Dopa¬
mine itself does not penetrate the blood-brain barrier, so as such
cannot be used directly to supplement the reduced levels in these
patients. L-dopa, however, can penetrate the blood-brain barrier
and can be used to good effect. Peripheral conversion of admin¬
istered L-dopa to dopamine by dopa decarboxylase may, however, lead
to a number of unwanted side effects. This problem can be overcome
by administration of a dopa decarboxylase inhibitor, such as carbi-
dopa, in conjunction with the L-dopa, for instance in the form of
the drug Sinemet.
The finding of a raised plasma 5-S-CD in one patient being
treated with this drug prompted the study of other patients under¬
going the same treatment. A further 5 patients undergoing treatment
with Sinemet were found to have elevated 5-S-CD levels, compared
with 3 patients with Parkinsonism being treated with amantadine, all
of whom had normal 5—S—CD levels. It was not possible to obtain
samples from patients with untreated Parkinsonism. The findings
of raised plasma 5-S-CD levels in these patients is in keeping with
the finding of elevated urinary excretion of 5-S-CD in patients
undergoing treatment with dopa and carbidopa (Stewart et al., 1983).
The obvious explanation for the raised plasma 5-S-CD levels in pat¬
ients being treated with Sinemet is one of increased availability
of substrate for 5—S—CD production. The large amount of L-dopa
being given to the patient is not decarboxylated to dopamine, a
major metabolite, due to the presence of carbidopa, and is avail¬
able for incorporation into other biochemical pathways, for instance
the tyrosinase pathway, leading to the production of 5-S-CD (Fig.4.2).
Whether this increased production of 5-S-CD is due to formation
by the melanocytes via the tyrosinase pathway, which would require
uptake of the dopa by these cells, or whether this represents some
non-tyrosinase production of 5-S-CD, as discussed on page 136, is
not clear. Whatever the mechanism, this finding of high 5-S-CD
levels in patients being treated with L-dopa points to a further
potential source of false positively high 5-S-CD levels in patients
with melanoma, and, although likely to be a very rare finding, the
presence of one such patient in the study of melanoma follow-up
patients suggests that this possibility should not be forgotten in
any studies of such patients.
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1) Plasma 5-S-CD levels in healthy individuals are not greatly
affected by unavoidable sun exposure in a temperate climate such
as that of S.E. Scotland, and studies of 5-S-CD levels in this
climate need not, therefore, be restricted to those months of the
year when sunlight is minimal.
2) Plasma 5-S-CD levels can be greatly influenced by exposure to
UVR therapy (UVB) or photochemotherapy (PUVA). Patients with
psoriasis treated with these types of UVR developed a near two-fold
increase in their plasma 5-S-CD level within the first 5 treatments,
before pigmentation developed, with subsequent increments of up to
4 times the pre-treatment level being found in the PUVA group.
3) Dithranol treatment caused an increase in plasma 5-S-CD in
some psoriatic patients.
4) Differences in skin and hair colour do not appear to result in
differences in plasma 5-S-CD levels.
5) Measurement of plasma 5-S-CD is of no value in the diagnosis
of stage I melanoma.
6) Plasma 5-S-CD is raised in 60 percent of patients with stage
III melanoma. Raised values are independent of the site of the
metastases. Normal 5-S-CD levels in patients with stage III
melanoma may be related to the amelanotic nature of the secondary
tumour tissue in these patients.
7) 10 percent of treated stage I and stage II melanoma patients
developed stage III melanoma during a study period of 20 months,
whilst undergoing follow-up. In approximately half of these
patients a raised plasma 5—S-CD level was observed prior to clinical
detection of metastases.
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8) Plasma 5-S-CD levels are not raised in patients with non-
melanoma tumours of the types studied.
9) Plasma 5-S-CD is rarely raised in patients with chronic inflamm¬
atory liver disease.
10) Plasma 5-S-CD may be raised in patients with poor glomerular
function.
11) Plasma 5-S-CD levels may be greatly increased by the adminis¬
tration of L-dopa, as seen in a number of patients being treated
for Parkinson's disease.
12) Plasma 5-S-CD levels in tyrosinase-negative albino patients
are no different from those in normally pigmented controls, suggest¬




The following list contains all chemicals and solvents used
in these studies, and their suppliers.
Bio-Rad Laboratories Ltd., Watford, Herts., U.K.
AG50W-X8 cation exchange resin (200-400, H+).
Camlab Ltd., Cambridge, U.K.
Woelm Neutral Activity Grade I aluminium oxide.
Fluorochem Ltd., Glossop, Derbyshire, U.K.
Methanesulphonic acid (puriss).
MacFarlane Robson Ltd., Glasgow, U.K. (BDH suppliers)
Acetic acid; 2-amino-2-(hydroxymethyl)propane-l,3-diol (Tris);
disodium hydrogen orthophosphate; ethylenediamine tetraacetic
acid tEDTA); hydrochloric acid; orthophosphoric acid; perchloric
acid; potassium dihydrogen orthophosphate; potassium iodide;
sodium acetate trihydrate; sodium hydroxide; sodium sulphate.
All BDH chemicals were AnAlar grade.
May and Baker Ltd., Dagenham, Essex, U.K.
Iodine (resublimed).
Scotlab Instrument Sales Ltd., Carluke, Lanarkshire, U.K.
Fisons HPLC grade methanol.
Sigma Chemical Co. Ltd., Poole, Dorset, U.K.
D-cysteine; L-cysteine; DL-dithiothreitol; D-{3-3,4-dihydroxy-
phenylalanine (dopa); glutathione (reduced); mushroom tyrosinase.
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Shandon Southern Products Ltd., Runcorn, Cheshire, U.K.




The following are the buffers used in these studies.
Sorensens phosphate buffer, pH 6'5
0*5M Na„HPO. titrated with 0*5M KH.PO. to give a pH of 6*5.2 4 2 4
Tris buffer, pH 8-6
1M Tris (2-amino-2-(hydroxymethyl)-propane-l,3-diol) titrated with
conc. HC1 to give a pH of 8*6.
The above buffers were prepared at 20°C.
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APPENDIX III
This appendix lists the abbreviations used in this thesis.
The abbreviations are defined both here and the first time they
appear in the text.
ACTH * adrenocorticotrophic hormone
ALM acral lentiginous melanoma
ALP alkaline phosphatase
ALT alanine amino transferase
CAT computerised axial tomography




GC-MS gas chromatography-mass spectrometry
HPLC high-performance liquid chromatography
LFT liver function test
LMM : lentigo maligna melanoma
MM malignant melanoma
8-MOP 8-methoxypsoralen
MSH melanocyte stimulating hormone
NM nodular melanoma
OCA oculocutaneous albinism




SSM superficial spreading melanoma
ty-neg OCA tyrosir.ase-negative oculocutaneous albinism
ty-pos OCA tyrosinase-positive oculocutaneous albinism
UVA long-wave ultraviolet radiation
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5-S-cysteinyldopa concentrations were determined by high-pressure liquid chromato¬
graphy and electrochemical detection in plasma from normally pigmented patients and
patients with oculocutaneous albinism, both tyrosinase-positive and tyrosinase-negative.
rhe plasma 5-S-cysteinyldopa concentrations were similar in all three groups, suggesting
that 5-S-cysteinyldopa can be produced by mechanisms which do not involve tyrosinase.
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Human oculocutaneous albinism is of two main types: tyrosinase-positive and tyrosinase-
negative albinism. These can be distinguished on the basis of both clinical features, and
presence or absence of tyrosinase activity in the hairbulbs (1).
Tyrosinase is thought to be essential for the first two steps in melanin synthesis. These
ire the hydroxylation of tyrosine to form dihydroxyphenylalanine (dopa) and the subse¬
quent oxidation of dopa to form the highly reactive intermediate dopaquinone. The
pathway leading to formation of the red/yellow phaeomelanins involves the spontaneous
coupling of dopaquinone with cysteine to form a number of different cysteinyldopas of
which quantitatively the major component is 5-S-cysteinyldopa (5-S-CD) (2).
5-S-CD can be detected in the urine of normal healthy individuals, regardless of skin or
pair colour (3). Patients lacking demonstrable tyrosinase activity would be expected to be
incapable of synthesising melanin or its precursors, including 5-S-CD.
We report the results of a study in which we measured plasma 5-S-CD concentrations in
poth tyrosinase-positive and tyrosinase-negative patients with oculocutaneous albinism to
see if it was possible to distinguish between the two groups on the basis of this measure-
nent.
VfATERIALS AND METHODS
rhere were twenty patients in the study, all with oculocutaneous albinism. They were divided into ten
yrosinase-positive and ten tyrosinase-negative albinos, on the basis of clinical assessment either on
ts own or, in a few cases, accompanied by a hairbulb tyrosinase test (4).
Controls were ten healthy volunteers of both sexes with a wide range of hair colour.
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Fig. I. Plasma 5-S-CD concentrations in albinos




Sampling from these 3 groups was not restricted to any particular time of year, as we had previously
demonstrated that the increases in plasma 5-S-CD levels observed during the summer months in
Edinburgh, although significant, were not of sufficient magnitude to invalidate any results obtained
during these months (5).
Blood samples were collected into lithium heparin tubes containing dithiothreitol to a final concen¬
tration of 5 mmoles/1. 5-S-CD was extracted from the plasma by adsorption onto alumina at pH 8.6
followed by elution with 0.2 M HC104. 5-S-CD determination was by high-pressure liquid chromato¬
graphy (HPLC) with electrochemical detection (6), and using 5-S-D-cysteinyl-L-dopa as internal
standard.
RESULTS
The plasma concentrations of 5-S-CD found in controls and albino patients are given in
Fig. 1.
Statistical analysis of the results using an independent T-test, showed that the three
groups of results were not significantly different from one another.
DISCUSSION
We have found no significant difference between plasma concentrations of 5-S-CD in
normally pigmented controls and in patients with oculocutaneous albinism, or between 5-
S-CD concentrations in tyrosinase-positive and tyrosinase-negative albinos.
The finding of measurable, and indeed apparently normal concentrations of 5-S-CD in
plasma from tyrosinase-negative albinos is perhaps surprising in the light of a demonstra¬
ble lack of active tyrosinase in the hairbulbs of these patients (1). However, Aquaron et al.
were able to demonstrate urinary excretion of 5-S-CD in both tyrosinase-positive and
tyrosinase-negative albino negroes in the sunny climate of Cameroon (7).
5-S-CD has been shown to be present in non-melanogenic tissues, such as liver, kidney
and brain, of mice and rats, as well as in hair of albino mice (8). In these cases the amino
acid is present mainly in a protein-bound form, free 5-S-CD being excreted in the urine.
The finding of 5-S-CD in these tissues, in which tyrosinase is not detectable, indicates that
it can be produced by some oxidation mechanism which clearly does not involve tyrosin¬
ase, although the importance of this enzyme in melanin production within melanocytes is
not open to question (2).
Similar tyrosinase-independent pathways have also been proposed as a result of work on
guinea-pig tissues, including kidney, spleen, heart and sympathetic ganglia, and on the
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ganglion stellatum of the cow (9, 10). Ito et al. have, in fact, demonstrated the formation of
cysteinyldopas in vitro from dopa and cysteine by a number of systems not involving
tyrosinase, including peroxidase-H202, and superoxide and hydroxyl radicals (11, 12, 13).
It seems likely that the presence of protein-bound 5-S-CD in tissues of mice and rats,
including the albino mouse, is due to its synthesis from protein-bound dopa, perhaps by
one of the non-specific oxidation mechanisms previously mentioned. Protein-bound dopa
is found in high concentrations in these tissues relative to the concentrations of free dopa,
and is presumably produced by the action of the enzyme tyrosine hydroxylase on tyrosine.
Turnover of the 5-S-CD-containing proteins would account for the excretion of the amino
acid in the urine of the rats and mice studied, including the tyrosinase-negative albino
mice, in which urinary excretion of 5-S-CD was found to be very similar to that in
pigmented animals. Without further investigation in humans it is difficult to explain our
observations in tyrosinase-negative albinos, but production of 5-S-CD in these individuals
would certainly appear to be by some non-tyrosinase-dependent oxidation pathway, and
could perhaps involve one or more of those suggested by 5-S-CD production in non-
melanogenic tissues. Reactive oxygens, for instance, are known to be produced in many
biological processes.
The findings in human albinos are certainly comparable to findings in albino mice, and it
may be that similar mechanisms for production of 5-S-CD are operating in the two species.
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